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Peptide! immunotherapy! (PIT)! is! a! specific! immunomodulatory! treatment! aiming! to! tip! the!
balance! from! pro8inflammatory! attack! to! restoration! of! immune! tolerance.! It! has! been!
successfully! translated! into! clinical! practice! in! the! field! of! allergy,! stimulating! ongoing!
research! in! autoimmune! diseases! including! type! 1! diabetes.! The! safety! and! mechanistic!
effects! of! proinsulin! C198A3! (PI! C198A3),! a! HLA8DR4! restricted,! naturally! processed! and!





over! the!6!month! treatment!period,! T! cell! receptor! (TCR)! clonotyping! and! gene!expression!




This! study! concludes! that! peptide! immunotherapy! using! PI! C198A3! is! a! safe! and! well8
tolerated! treatment! in! newly8diagnosed! adults! with! type! 1! diabetes;! deployment! of! novel!






































the! most! successful! recruitment! site! numerically),! and! I! was! a! key! part! of! the! trial!
management!group! (principally!Colin!Dayan! (CD),!Mark!Peakman! (MP),!Rachel!Stenson!and!
the!PIs! from! the!other! recruiting! sites)!which!met!monthly!by! teleconference! to! guide!and!
oversee! conduct! of! the! trial.!With!MP,! CD! and! Dr!Mohammad! Ahadj! Ali! I! was! part! of! the!
writing!group!for!the!submitted!manuscript!(on!which!I!am!joint!first!author)!that!reports!the!
trial! outcomes,! and! the! key! findings! from! this! are! reported! here! in! Chapter! 4! to! provide!
context!for!my!own!laboratory!studies.!!!
I! performed! all! of! the! assays! described! in! this! thesis! myself,! except! where! specified.! For!
clarity!I!would!like!to!indicate!the!following:!!
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cell! destruction! rendering! most,! if! not! all,! individuals! dependent! on! life8long! exogenous!




advances! in! insulin! therapy! and! delivery,! patients! are! still! exposed! to! glucose! excursions!
leading! to! complications! of! hyperglycaemia,! such! as! cardiovascular! disease,! retinopathy,!
neuropathy!and!nephropathy,!as!well!as!the!risks!of!hypoglycaemia.!In!addition,!as!a!chronic!









Type! 1! diabetes! is! a! complex! multifactorial! genetic! disorder! and! in! recent! years! newer!
technologies! such! as! genome8wide! association! (GWAS)! studies! have! allowed! greater!










Single! nucleotide! polymorphisms! (SNPs)! of! major! non8HLA! encoding! genes! also! have! an!
associated!risk!to!T1D!although!this!risk!is!far!below!MHC!class!II!alleles.!These!SNPs!include!
variants! in! the! insulin! (INS)! gene,! protein! tyrosine! phosphatase! non8receptor! type! 22!
(PTPN22),! cytotoxic!T8lymphocyte8associated!protein!4! (CTLA:4)!and! the! IL82! receptor!alpha!
chain!(IL2RA)15.!The!identification!of!these!SNPs!gives!clues!to!the!pathogenesis!of!T1D!being!
closely! linked!to!T8cell!signalling!with! insulin!being!a!major!autoantigen,!PTPN22! involved!in!
negative!regulation!of!TCR!signalling,!CTLA:4!a!co8stimulatory!molecule!which!down8regulates!
T8cell!activation!and!IL:2RA!being!a!T8cell!signalling!receptor.!
There! is! a! lack! of! concordance! for! T1D! in!monozygotic! twins,!with! a! 39%!probability! at! 40!
years! for! a! discordant! monozygotic! twin17.! This! highlights! the! influence! of! environmental!
factors! in! risk! of! T1D.! Within! the! increasing! incidence! of! new! T1D! cases! there! is! a! trend!
towards! disease! presenting! in! less! high! risk! DR3* and* DR4* genotypes18–21and! even! within!
protective!genotypes18,!suggesting!that!the!rise!in!incidence!is!no!longer!reliant!on!a!genetic!
predisposition!but!increasingly!swayed!by!environmental!pressures.!!
Preclinical! signs! of! autoimmunity! appear! early! in! life! with! the! presence! of! autoantibodies!
(AAb)!detectable! in! the!high! risk! from! less! than!6!months!of! age22.! This!would! suggest! the!
importance! of! prenatal! or! early! infancy! environmental! factors.! Maternal! age! and! heavier!
baby! weight! have! been! associated! with! T1D! risk23,! with! increasing! weight! of! children! a!
defence! for! the! “accelerator!hypothesis”!which! suggests! the! increasing!demands!on!β8cells!
accelerates!their!decline24.!
A! meta! analysis! of! risk! of! T1D! in! children! delivered! by! Caesarean! section! showed! an!
approximate! 20%! increase25.! The! gut! microbiome! is! important! in! shaping! a! developing!
immune! system! and! Caesarean! section! appears! to! reduce! the! diversity! of! gut! microbiota!
compared!to!vaginal!birth! in!the!early!years!of! life26.!Some!have! linked!this!to!the!“hygiene!
hypothesis”27,!suggesting!reduced!exposure!to!infections!at!a!young!age!leads!to!immaturity!
of! the! immune! system! and! higher! risk! of! immune8modulated! disorders.! Comparing! gut!
microbiome!in!children!with!or!without!antibody!(Ab)!positivity!no!differences!were!seen!in!
bacterial! diversity,! microbial! composition,! or! single! genus! abundances! but! substantial!







via! sunlight! exposure,! as! potential! influences.! Viral! infections,! in! particular! enteroviruses,!
echo! this! seasonal! variation31.! The! identification!of! a! SNP!within!an! innate! immune! system!
receptor,! interferon8induced!with!helicase!C!domain!1!(IFIH1),!which!encodes!for!a!receptor!




As! a!modulator! of! the! immune! system! vitamin!D! has! been! linked! to! autoimmune! disease,!
especially! as! geographical! variations! in! disease! incidence! correlate!with! sunlight! exposure.!
Interestingly!a!plateauing!of!the!rise!in!incidence!of!T1D!in!Finland!after!2003!has!coincided!
with! the! introduction! of! vitamin! D! fortification! of! dairy! products35! and! a!meta! analysis! of!
observational!studies!showed!a!positive!effect!of!vitamin!D!supplementation36;!nonetheless!
major! intervention! studies! have! yet! to! be! reported! and! small! scale! studies! have! shown!
conflicting!results37,38.!!
Dietary! factors! in! childhood! have! been! implicated! as! triggers! for! T1D.! Whilst! prospective!
studies! of! breast8feeding39! and! removal! of! bovine! insulin40! from! cow’s! milk! formula! in!
genetically! at8risk! infants! showed! a! protective! effect! on! progression! of! islet! autoimmunity,!
feeding! a! hydrolysed! infant! formula! in! those! at! genetically! high! risk! did! not! reduce! risk! of!
progression! to! antibody! positivity! over! 7! years41.! ! Further! analysis! of! long8term! effects! of!






The!putative!natural!history!of! T1D!was!described!by!Eisenbarth!et! al.1! in!1986,! suggesting!
that! genetic! predisposition!with! the! presence! of! unknown! triggers! leads! to! autoimmunity,!





period! of! subclinical! autoimmunity! and! gradient! of! the! β8cell! decline! varies! between!
individuals,!which!is!illustrated!by!the!effect!of!age.!Recently!the!JDRF,!the!Endocrine!Society!
and! the! American! Diabetes! Association! issued! a! scientific! statement! clarifying! the!
presymptomatic!stages!of!T1D44.!This!statement!highlights!the!need!to!recognise!the!disease!
continuum! from! the! presence! of! two! or! more! islet! autoantibodies! with! normoglycaemia!
(presymptomatic!stage!1),!through!to!the!presence!of!β8cell!autoimmunity!with!dysglycaemia!
(presymptomatic!stage!2),!and!onset!of!symptomatic!disease!(stage!3).! !Acknowledging!that!








Eisenbarth’s! original! depiction! of! β8cell! mass! in! T1D,! showed! a! constant! decline! with! the!





previously! thought! and! β8cell! decline! is! a! non8linear! process.! Although! at! the! time! of!
diagnosis! it! is! estimated! that! 90%! of! functional! β8cell! mass! has! been! destroyed46,! the!
Diabetes! Control! and! Complications! Trial! (DCCT)! established! that! 20%! of! patients! still! had!
detectable! insulin! production! at! 5! years! post! diagnosis47.! With! newer! more! sensitive! C8
peptide! assays! β8cell! function! has! been! detected! in! 10868%48,49! of! patients! greater! than! 3!
decades!after!diagnosis!with!80%!of!those!with!detectable!C8peptide!showing!a!physiological!
rise! to!a!meal! stimulus49.!Those!older!at!diagnosis!are!more! likely! to!have!higher!C8peptide!





cell! salvage.!Decline! in!β8cell! function! is!not!necessarily! a! smooth!progression,!oral! glucose!
tolerance! test! (OGTT)! data! from! the! Diabetes! Prevention! Trial81! (DPT81)! showed! a!
“ratcheting”!remitting!relapsing!of!glucose!tolerance!during!the!period!from!3.8!years!prior!to!
diagnosis!with!some!individuals!developing!transient!hyperglycaemia!post!OGTT,!before!overt!
diabetes54.! This! was! considered! to! be! due! to! fluctuations! in! insulin! sensitivity,! as! glucose!
fluctuations! did! not! correlate! to! early! C8peptide! responses.! The! decline! in! stimulated! C8
peptide!is!noted!to!have!an!accelerated!fall!in!the!3!months!prior!to!symptomatic!diagnosis55,!
whilst! fasting! C8peptide! are! maintained56.! Although! immune! interventions! would! ideally!
target!subjects!with!maximal!residual!β8cell! function!before!signs!of!autoimmunity! (primary!
prevention)! or! after! detection! of! autoimmune! markers! such! as! islet! autoantibodies!
(secondary!prevention),!this!can!be!difficult! in!terms!of!targeting!a!healthy,!often!paediatric!
population! for! large8scale! immune! therapy! trials.! Salvaging! β8cell! reserve! at! diagnosis!
(tertiary!prevention)!or!beyond!offers!a!viable!option!as! residual!endogenous!secretion!can!
still!improve!glycaemic!control,!protecting!against!complications!and!hypoglycaemia57,58.!!!!
Study! of! the! subclinical! stage! can! been! difficult! with! large,! long8term! screening! studies!
required! in! paediatric! cohorts,!with! the! added! problem! of! a! lack! of! reliable! biomarkers! to!
track!disease!progression.!A!number!of! longitudinal! studies! in!high8risk!groups,! such!as! the!
TrialNet! Natural! History! Study59! and! the! DPT8160! have! tracked! emerging! autoimmunity!
through!islet!autoantibody!development.!Islet!autoantibodies!are!the!first!markers!of!disease!
development,!developing!before!the!decline!in!β8cell!mass!triggers!hyperglycaemia.!The!main!




decarboxylase!antibody! (GADA),! tyrosine!phosphatase8like!protein!antibody! (ICA512A!or! IA8
2A),!and!zinc!transporter!8!antibody!(ZnT8A).!The!most!common!islet!autoantibody!to!arise!in!
those! at! risk! is! GADA! and! risk! of! developing! autoantibodies! (IAA,! GADA! or! IA82A)! declines!
with!age59.! !Tracking! the!presence!of!autoantibodies!has!again!highlighted!heterogeneity! in!
disease! development,! for! example,! IAA! positivity! is! more! likely! to! be! present! in! children!
under!the!age!of!8!and!more!likely!to!progress!to!multiple!antibody!positivity,!where!as!GADA!








disease! course.! Emerging! technologies! and! greater! characterisation! of! the! genetic! and!




Currently! genotyping! for! high8risk! alleles! and! autoantibody! testing! are! used! in! prevention!
trials! to! identify! those! at! risk,! sometimes! with! the! addition! of! glucose! tolerance! tests.!
Participants! in!the!Diabetes!Autoimmunity!Study!of!the!Young!(DAISY)!trial!were!genotyped!
for! 20! non8HLA! SNPs! in! addition! to! HLA! genotypes62.! From! these! data! they! were! able! to!
identify!5!high8risk!predictors:!1)!a!PTPN22! gene!polymorphism!2)!a!UBASH3! SNP!3)!an! INS!
gene!polymorphism!4)!a!family!history!of!type!1!diabetes!and!5)!HLA:DR3/4.!UBASH!belongs!
to!a! family!of! cell! regulators! linked! to!down8regulation!of! receptor8induced!activation! in!T8
cells63.!Combining!these!risk!factors!gave!hazard!ratios!up!to!16!for!the!development!of!islet!
autoimmunity!and!>40!for!diabetes.!Further!modelling!using!microarray!gene!expression!data!
from! peripheral! blood! RNA! in! the! antibody! positive! group! from! DAISY,! identified! and!
confirmed! four! multigene! models! that! consistently! stratify! high8! and! low8risk! subsets! of!








in! first8degree! relatives! of! T1D! patients! by! ELISA.! Significant! correlation! was! revealed!
between! two!closely! related! chemokines!CCL3!and!CCL4! in! individuals! at! risk!with!multiple!
positive! islet! autoantibodies! (r=0.84,! P=0.00005),! not! present! in! the! autoantibody8negative!
group65.! These! T! helper! 1! (TH1)! derived! chemokines! were! also! found! to! be! elevated! and!
correlated!to!β8cell!function,!in!serum!samples!collected!from!256!children!and!adolescents,!
studied! longitudinally! for! a! year! post! diagnosis66.! Other! chemokines! such! as! CXCL10! have!
been! implicated! in! disease! with! this! example! being! found! at! elevated! levels! in! pancreatic!
biopsies! of! those! newly! diagnosed67,! as!well! as! systemically! in! newly! diagnosed! children68.!













distort! these! variables.! Although! measurement! of! autoantibodies! is! also! suggested! in! the!
same!guidelines! as! an!outcome,! it! is! acknowledged! that! these!do!not! necessarily! correlate!
with!benefit.!Urinary!C8peptide! is!becoming! increasingly!validated!as!a! surrogate!marker!of!





Again,! immune! markers! would! be! useful! in! this! setting! and! in! a! study! using! multivariate!
logistic!regression!models!to!predict!residual!β8cell!function!up!to!one!year!after!diagnosis,!a!
meta8immunological! profile! measuring! age,! body! mass! index! (BMI),! fasting! C8peptide,!
number! of! circulating! CD3+CD16+CD56+! cells! and! the! percentage! of! CD1c+CD198CD148
CD3038! type!1!myeloid!dendritic! cells! (mDC1s)! at!disease!onset!had!a! significant!predictive!




monitoring! (HBGM).! HbA1c! is! able! to! give! an! approximation! of! glycaemic! control! over! the!
previous!3!months;!however!glucose!excursions!are!not!taken!into!account,!therefore!lability!
of! control! can! be!masked.! Home! blood! glucose!monitoring! is! a! simple!way! for! subjects! to!
track! glucose! control! and! gives! real8time! data! to! inform! management.! Nonetheless! its!
usefulness! is! operator! dependent! and! repeated! measurements! can! become! a! burden.!
Continuous! glucose! monitoring! systems! (CGMS)! are! available! but! cost! restrictions! largely!
limit!them!to!research!tools!at!the!moment.!Flash!glucose!monitoring!is!a!newer!technology!






CD8+!T8cell! interferon8γ! enzyme8linked! immunospot! (ISL8Spot)76! assay! offer! the! benefit! of!
revealing! an! antigen8specific! functional! response! by! cytokine! output! in! vitro,! and! are!
therefore!attractive!options!as!biomarkers!of!response!to!antigen!specific!immunotherapy.!!
Caution!must!be!taken!as!few!immune!biomarkers!are!validated!and!in!fact!immune!changes!
may!not! reflect!outcomes.! For!example! in!a! trial!of! rapamycin!and! IL82! in!newly!diagnosed!
patients,! Treg! markers! rose! but! despite! this! β8cell! function! declined.77! Specificity! of!
biomarker! to! disease,! lag8time! between! treatment! and! outcomes,! functionality! of! immune!







cohort! as! a!whole,! such! as! those!with! baseline! titres! of! insulin! autoantibodies! >80! nU/mL!
within! the! oral! insulin! arm! of! the! DPT81! trial78.! Similarly! in! anti8CD3!monoclonal! antibody!
trials! post! hoc! analysis! identified! sub8groups! within! the! newly! diagnosed! population! that!











autoantibodies!providing! an! indicator!of! disease!without!direct! causation.!Diabetes8specific!
autoreactive! T8cells! can! be! found! in! healthy! controls! as! well! as! individuals! with! T1D85,!
signifying! that! regulatory! factors!normally!present!are! lost! in!diabetic! individuals! leading! to!
disease! through! breakdown! of! peripheral! tolerance.! This! delicately! held! balance! between!
disease! and! tolerance! appears! to! hinge! on! the! actions! of! regulatory! T8cells! (Tregs).! Co8
transfer!of!CD4+/CD25+!Treg! cells!with!autoreactive!T8cells! from!non8obese!diabetic! (NOD)!
mice! into! T8cell! deficient! NOD.SCID! mice! prevents! induction! of! diabetes! 86.! In! preclinical!
models! of! T1D! and! human! studies,! functional! defects! in! Tregs! have! been! identified! as!
possible!causes!of!loss!of!tolerance!87–89.!
Immunotherapy! for! diabetes! targets! the! disease! at! its! core,! aiming! to! halt! autoimmune!
destruction! of! β8cells.! Early! studies! in! the! 1980s! gave! proof! of! concept! that!
immunosuppression! with! agents! such! as! cyclosporine90,! azathioprine! and! prednisolone91!
could!lead!to!remission!of!β8cell!destruction!and!metabolic!improvements!at!least!in!the!short!
term.!However! generalised! immunosuppression! raises! concerns! over! non8specific! targeting!









CD20! treatment! in! multiple! sclerosis92.! Whilst! T1D! is! classically! thought! to! be! a! T8cell!
mediated!disease,!there!is!evidence!that!this!may!be!over8simplistic.!For!example,!it!has!been!
shown! that! B8cells! can! be! a! factor! in! disease! pathogenesis.! B8cells! are! part! the! infiltrative!
process!seen!in!insulitis!being!the!second!most!prominent!cell!type82,!and!can!act!as!antigen!
presenting! cells! using! MHC! class! II.! The! role! of! B8cells! in! disease! progression! was!
strengthened! with! the! success! of! selective! B8cell! depletion! using! the! anti8CD20! antibody!




peptide! levels! albeit! delayed94.! There! have! been! concerns! with! a! high! number! of! infusion!
reactions! linked! to! cytokine! release! and! the! potential! risk! of! progressive! multifocal!
leukoencephalopathy! which! has! been! seen! after! rituximab! use! in! other! immune8mediated!
diseases!such!as!rheumatoid!arthritis!and!systemic!lupus!erythematosus95.!Anti8CD3!antibody!
use! in! T1D! has! been! clinically! studied! with! two! humanised! Fc! engineered! antibodies,!
teplizumab96! and! otelixizumab97! showing! initial! promise! with! improvements! in! C8peptide!
levels.! In! order! to! try! and! reduce! adverse! events! in! phase! III! studies! significant! dose!
reductions!were!made,!in!the!case!of!otelixizumab!the!dose!was!reduced!from!a!total!dose!of!
48864mg!from!the!previous!study96!to!a!total!dose!of!3.1mg!in!the!DEFEND8198!and!DEFEND8
299! studies.!Reducing! the!dose! to! less! than!one8tenth!of! the!previous!effective!dose!would!
likely!have!negated!not!only!the!adverse!events!but!also!the!beneficial!effects!of!treatment,!
with!both!the!phase!III!proving!to!be!non8efficacious.!Despite!the!fact!that!the!Protégé!study!
using! teplizumab!failed! to! reach!an!unvalidated!primary!composite!endpoint!of! insulin!<0.5!
U/kg/day! and! HbA1C! <6.5%! (48! mmol/mol)! at! 1! year,! further! analysis! showed! significant!







administration! in!NOD!mice! can! suppress! or! reverse! established! T1D! and! increase! FOXP3+!
Treg! levels! 101,102.! Recombinant! IL82! is! currently! in! clinical! use! for! treatment! of! metastatic!
renal!cell!carcinoma,!but!potential!benefits!of! IL82!in!T1D!have!to!be!balanced!by!toxicity!of!
systemic! IL82.! Low! dose! IL82! studies! in! children! and! adults! with! T1D! are! in! progress!
(ClinicalTrials.gov:!NCT01862120!and!NCT02265809).!The!combination!of!IL82!and!rapamycin!
(an! inhibitor! of! mammalian! target! of! rapamycin! complex! (mTORC)! activation)! has! been!
successful!in!prevention!of!spontaneous!diabetes!and!recurrent!diabetes!after!islet!transplant!
in! the!NOD!mouse103.! Rapamycin! inhibits! Th17! and! Th1!proliferation!with! lesser! effects! on!




from!other! conditions! (in! this! case! the! success! of! IL82! and! rapamycin! combination! in! graft!
versus!host!disease)!which!can!have!unique!responses.!!
1.6 Antigen'Specific'and'Peptide'Immunotherapy'
Antigen8specific! immunotherapy! (ASI)! offers! a! targeted! approach! to! modulating! the!
autoimmune!process!towards!tolerogenic!responses!compared!to! immune!suppression.!The!
aim!is!to!re8establish!tolerance!by!administration!of!an!autoantigen,!which!can!be!in!the!form!
of!whole!antigen!or!as!peptide! immunotherapy! (PIT),!using!peptides!derived! from!antigens!
(Figure!2).!Use!of!peptide!epitopes!has!potential!benefits!over!whole!antigen!administration!
such!as!ease!of!use,!enabling!a!pure!highly!concentrated!epitope!to!be!delivered!at!lower!cost!
and!higher!solubility! than!whole!antigen!and!without! the! risk!of!complications!of!biological!
activity105.! These! properties! also! simplify! methods! to! combine! multiple! peptides! for! more!
efficacious!therapy106.!As!natural!processing!of!the!antigen! is!bypassed,!choice!of!peptide! is!
important! as! it! is! imperative! to! isolate! a! peptide!which! is! biologically! valid107! and! disease8
specific.! Identifying! peptides! that! are! naturally! processed! and! presented! epitopes! (NPPEs)!
should! ensure! that! such! epitopes! are! able! to! elicit! a! T8cell! response! by! directly! binding! to!
HLA,!and!also!increase!the!chance!that!such!epitopes!are!present!in!vivo!in!pancreatic!islets!
or! lymph!nodes!through!MHC!class! II!presentation.!Cryptic!peptides!are!those!not!naturally!
processed! and! presented! and! these! can! incur! a! higher! risk! for! adverse! effects.! Altered!
peptide! ligands! (APLs)!are!a! form!of! cryptic!peptides,! that!have!amino8acid! substitutions! in!






options!with! the! exception! of! glatiramer! acetate,! a! 4! amino8acid! peptide! based! on!myelin!
basic!protein!(MBP)!currently!used!in!multiple!sclerosis109.!
Figure' 2:' Areas' of' research' into' antigen' specific' immunotherapy' and' peptide'
immunotherapy.''































































model112.! A! transgenic! HLA8DR1! mouse! was! sensitized! to! Fel! d! 1! (cat! allergen)! by!
intraperitoneal! administration! of! antigen! in! the! presence! of! alum! as! an! adjuvant,! this!was!




HA(3068318)! peptides! intradermally.! Mice! given! the! HA(3068318)! peptide! showed! extensive!
peribronchial!and!perivascular!inflammatory!infiltrates!not!present!in!the!Feld(29845)!group.!The!
Feld(29845)! treatment!was! able! to! significantly! increase! the!proportion!of! IL810+!CD4+! T8cells!
compared!to!control!peptide.!This!IL810!would!appear!a!crucial!mediator!of!tolerance,!as!an!
IL810!receptor!blocker!was!able!to!negate!the!effects!of!PIT.!!There!were!also!signs!of!linked!
suppression! or! intramolecular! tolerance,! with! reduced! proliferation! of! DR1Feld1(29–45)!
tetramerneg!cells!in!response!to!other!DR18restricted!epitopes!of!Fel!d!1!after!desensitisation.!











ASI! is! thought! to! induce! tolerance! through! induction!Treg!populations!which!promote! self8
tolerance! through! secretion! of! cytokines! such! as! IL810115,! TGF8β! and! IL84116! or! reduction! of!
IFN8γ117–119.!The!importance!of!IL810!production!in!PIT!can!be!highlighted!with!neutralisation!
of! this! cytokine.! The! use! of! an! anti8IL810! monoclonal! antibody! in! transgenic! (Tg4)! mice!
expressing!a!TCR!specific! for! the!N8terminal!peptide!Ac1–9!of!MBP! tolerized! to!EAE!by!PIT,!
abrogated!the!effects!of!PIT!and!rendered!the!animals!susceptible!to!disease!induction120.!The!
concept!of!bystander!suppression! is! thought! to!be! important! in!PIT,!by!which! induced!Treg!
cells!are!capable!of!homing!to!the!autoimmune!target!site!and!secreting!cytokines!such!as!IL8
10,! IL84! and! TGF8β! in! response! to! release! of! local! autoantigens,! leading! to! silencing! of!
aggressive! Teff! also! reacting! to! these! autoantigens116.! In! a! mouse! model! of! virus! induced!





to! third! party! antigens! presented! by! the! same! APC121.! This! phenomenon! could! potentially!
counterbalance!the!action!of!epitope!spreading!which!propagates!autoimmune!targets!with!
increasing! damage! to! the! β8cell,! whilst! also! keeping! suppression! specific! to! the! disease!
process!and!avoiding!suppression!of!normal!responses.!!!!!
High!doses! in! PIT! can! lead! to!deletion!of! pathogenic! cells! likely! through! activation8induced!
cell! death122,! as!well! as! suppression! of! proliferative! responses! to! antigen122.! This!was! seen!
with! 100μg! doses! of!myelin! basic! protein! peptide! Ac(189)! used! intranasally! in! EAE!mice120,!
and! oral! ovalbumin! (5! doses! of! 58500mg)! in! mice! transgenic! for! ovalbumin8specific! T8cell!
receptor! genes122.! It! has! been! suggested! that! deletion! of! high8affinity! TCRs! in! response! to!
high!doses!may!induce!tolerance!by!leaving!intact!low8affinity!T8cells!that!respond!poorly!to!
antigen! in! the! absence! of! IL82.! Lower! doses! may! select! induction! of! antigen8specific! cells!
which!produce!TGF8β,!IL84!and!IL810122.!
McPherson!et!al.123!recently!reported!on!the!role!of!programmed!cell!death!protein81!(PD81)!
after! PIT! in! a! mouse! model! of! experimental! autoimmune! encephalomyelitis! (EAE).! PD81,!




from!Tg4!mice!were! introduced! into!B10.PLxC57BL/6!mice,! then!the!Ac189(4Tyr)!peptide!or!
PBS!was! administered!before! an! attempt! to! induce! EAE!with! peptide! in! CFA! adjuvant.! The!
Ac189(4Tyr)!peptide!was!able!to!prevent!EAE!after!just!one!dose.!Transferred!naïve!Tg4!T8cells!
had!higher! levels!of!PD81! in!PIT! treated!mice!compared! to!PBS! treated! (Figure!3A)!and! this!
higher!level!was!sustained!at!day!4!and!day!7!(Figure!3B).!T!effector!cells!(Teff)!exposed!to!PIT!
showed!high!PD81!levels!for!over!2!weeks!and!when!transferred!into!a!secondary!host!these!
Teff! cells! failed! to! induce! disease,! which! the! authors! considered! as! “silencing”! of! the! Teff!
function.! ! Interestingly!although!the!authors!saw!reduced! levels!of! IFNγ!and! IL817! from!Tg4!
cells!isolated!from!the!spleen!post!PIT,!they!did!not!witness!an!elevation!in!the!frequency!of!
FoxP3+! donor! Tg4! cells! or! in! the! IL810! response.! PD81! blockade! on! splenocytes! post! PIT!
allowed! these! cells! to! exhibit! IFNγ! and! IL17! responses! to! peptide! stimulation! (Figure! 3C).!
Using! a! PD81! knockout! mouse! Tg4.PD81−/−! as! a! donor! prevented! subsequent! PIT! from!




induction! of! tolerance! by! PIT! in! a! PD818/8! knock8out! mouse! induced! by! transfer! of! naïve!
OVA(3238339)(pOVA)!peptide!reactive!T8cells125.!!!
Compared! to! other! EAE!mouse!model!work,! the! lack! of! IL810! response!was! unusual! as! PIT!
with!Ac189!has!resulted!in!an!increase!in!antigen!specific!CD4+!T8cell!release!of!IL810120.!
The! authors! were! able! to! illustrate! a! mechanism! of! suppression! through! reduction! in! 58
hydroxymethylcytosine!(5hmC)!and!hypomethylation!at!the!site!of!the!PD81(Pdcd1)!promoter!





PD:1* is* required* for* the* establishment*
and* * maintenance* of* tolerance* in* naïve*
CD4+* Tg4* cells.* (A–C)* B10.PL* mice*
received* PBS/PIT* 1* day* after* transfer* of*
naïve*CD4+*Tg4* cells.* (A)*Representative*
histograms* of* PD:1* expression* gated* on*
CD4+* Tg4* donor* cells* in* * spleen* 4* days*
after* PBS/PIT.* (B)* MFI* of* PD:1* staining**
gated*on*CD4+*Tg4*donor*cells* in*spleen*
4*and*7*days*after*PBS/PIT*(4–6*mice*per*
group,* from* one* of* three* experiments*
giving* consistent* results,* dotted* line*
represents* MFI* of* isotype* control*
staining).* (C)* IFN:γ* and* IL:17* production*
in* response* to* Ac1:9* by* splenocytes*
isolated*7*days*after*PIT*and*cultured* in*
the*presence*of*anti:PD:1*or*isotype*(four*
mice* per* group* from* one* of* three*
experiments* giving* consistent* results,*
dotted* lines*represent*cytokine* levels* for*
unstimulated* cultures).* (D)* EAE* in*
B10.PLxC57BL/6* mice* that* received*




Another!observation! in! Teff! cells!post!PIT!was! that! although! the!donor!Teff! cells! persisted,!
they!were!not!seen!infiltrating!the!CNS!and!were!more!confined!to!the!spleen.!On!examining!






with! lower! levels! seen! in! PIT! treated! Teff! cells.! Antibody! blockade! of! PSGL81! led! to!
attenuation!of!Tg4!Teff! cell!driven!EAE,! suggesting! that!T8cell! trafficking!via!PSGL81!may!be!
disrupted!by!PIT.!!!!!!
Dose!of!antigen!can! influence!mechanism!of!action,! this!was!explored! further! recently! in!a!




Figure' 4:' Dose' escalation' enhances' the' induction' of' IL$10+' CD4+' T$cells' in' addition' to'
minimising'the'risk'of'adverse'effects'during'immunotherapy.'From'Burton'et'al.'2014127'
Tg4*mice*were* treated* s.c.*with* 3x8μg* doses* of*MBP*Ac1:9[4Y],*with* or*without* prior* dose*
escalation,*as*illustrated*(a).*Splenocytes*were*cultured*for*five*days*with*10μg*ml:1*MBP*Ac1:
9[4K]*and*20U*ml:1*IL:2.*(b)*Scatter*plots*show*the*percentage*of*viable*CD4+*cells*which*are*
IL:10+,* horizontal* lines* show*means* for* each* column* (n=3).* One* of* two* experiments.* ** P* ≤*
0.05,* *** P* ≤* 0.01* one:way* ANOVA* with* Bonferroni* post:test,* comparing* peptide:treated*
groups* with* PBS:treated* control* group.* (c)* Onset* and* severity* of* EAE* in* mice* treated* as*







Changes! in! T8cell! transcriptome! were! tracked! using! whole! genome! expression! arrays! that!
found!that!expression!of!negative!co8stimulatory!molecules!including!Lag3,*Tigit!and!Havcr2*
(TIM83)! were! highly! upregulated! during! treatments! 186! of! EDI! and! were! maintained! with!
extended! high! dose! treatment.! Pdcd1(PD81)! and! Ctla4! remained! largely! unchanged,! whilst!
Btla! and!Cd274(PD8L1)!decreased!with!extended! treatment.!A!number!of! factors! though! to!
influence! IL810! production! by! CD4+! T8cells! were! upregulated! by! EDI,! such! as! Icos! and* Il10*




with! LAG83! and! PD81! as! good!markers! of! an! EDI! induced! anergic! CD4+! cell! population! and!
TIGIT!and!TIM83!as!markers!of!EDI!induced!IL810!secreting!cells.!Such!findings!offer!potential!
for! earlier! tracking! of! efficacious! tolerance! induction! through! peptide! immunotherapy!
intervention!trials.!!!
1.6.2 Safety'
Many! years! of! experience! of! ASI! in! allergy! and! asthma!have! generally! supported! its! safety!
profile!though!potential!risks!of!ASI!are!disease!acceleration!and!hypersensitivity!reactions.!In!
asthma,! the! use! of! Fel! d! 1! peptides! in! cat! allergic! asthmatics! can! lead! to! isolated! late!
asthmatic! reactions! which! is! felt! to! be! T8cell! dependent! and! IgE/mast! cell! independent128.!




may! be! involved! such! as! route! of! administration,! choice! of! peptide,! dose! and! use! of!





sclerosis! revealed! local! hypersensitivity! and! disease! progression! using! an! altered! peptide!
ligand!(APL)!of!myelin!basic!protein!MBP(83899)!named!CGP77116133!which!lead!to!termination!






for! up! to! 9! months.! Disease! progression! was! associated! with! a! skewing! towards! a! Th2!
phenotype!with!increased!IFN8γ!and!reduced!IL84.!Local!skin!reactions!of!pain,!reddening!and!
swelling! up! to! several! centimetres! in! diameter! were! seen! in! all! 8! patients! with! systemic!
hypersensitivity!reaction!in!one!patient.!
Apart!from!this!study!hypersensitivity! in!clinical!ASI!trials!are!rare.! In!preclinical!models,!ASI!
has! been! linked! to! fatal! anaphylaxis! in! the! NOD! mouse134! using! repeated! subcutaneous!
dosing! of! an! altered! peptide! ligand! of! an! insulin! peptide! B(9823)! (total! dose! >1mg).! The!
authors!were!later!able!to!avoid!hypersensitivity!by!manipulating!the!isoelectric!point!on!the!
same!peptide135.!!




systemic! symptoms! to! suggest! hypersensitivity.! These! reactions! appeared! to! be! dose8
dependent,! with! 11%! of! the! 10μg! dose! group! versus! 56%! of! the! 100μg! dose! group! being!
affected.! Although! the! reactions! could! recur! on! subsequent! doses,! they! did! not! have! a!
pattern!of!amplification.!The!investigators!also!found!no!evidence!of! induction!of! IgG!or! IgE!
anti8peptide!antibody!or!T!helper!type!2!(Th2)!IL84,!IL85!and!IL813!cytokine!responses.!This!led!





epitopes! in! humans142! and!NOD!mice143.! There! is! significant! evidence! that! derivatives! from!
insulin!or! its!precursors!act!as!targets!for!the! immune!attack! in!T1D,!by!CD4+!T8cells! in!DR4!
transgenic!mice144,! humans145,146! and! by! CD8+! T8cells! in! humans147.! This! in! addition! to! the!
prevalence!of! insulin!antibodies!in!newly!diagnosed!T1D!suggests!that! insulin,! its!precursors!









those!with! T1D!aged!3845! years.! There!were!2! study! groups,! split! into! treatment!with!oral!
insulin! or! twice! daily! subcutaneous! insulin! with! annual! four8day! continuous! intravenous!
infusions,!with!respective!control!groups!(Table!1).!Ultimately!neither!treatment!was!found!to!




at! least! 2! autoantibodies,! including! insulin! antibodies! and! normal! glucose! tolerance! was!
completed! in! 2016! with! results! recently! reported148.! These! showed! no! delay! overall! in!






exploratory!analysis! showed!that! those!with!better!adherence! rates! in! the!primary!stratum!
























































The!658kD! isoform!of! glutamic!acid!decarboxylase! (GAD)! is! a!major!autoantigen! in!patients!
with! T1D150! and! is! thought! to! be! one! of! the! earliest! targets! of! T8cell! reactivity! before!
spreading! of! the! response! to! other! epitopes151.! GAD! antigen! administered! intra8





one! month! apart! in! a! subgroup! of! those! treated! within! 6! months! of! diagnosis150.! In:vitro!
stimulation!of!PBMCs!with!GAD!showed!increased!responses!of! IL85,! IL810,! IL813,! IL817,! IFNγ!
and! TNFα,! but! not! IL86! and! IL812! between! baseline! and! 15! months150.! GAD8induced!
expression! of! transcription! factor! FOX8P3! and! TGF8β! was! increased! in! GAD8alum! group!





4!years!post!treatment,!showed!evidence!of! long8standing!preservation!of!β8cell! function! in!
the! 6! months! from! diagnosis! subgroup,! with! significant! differences! in! fasting! but! not!





antibody! levels,! there!were!have!been!no! signs!of! this! in!GAD! trials139,154–156.! !Despite!early!
promising!results,!a!larger!scale!phase!3!study!using!GAD8Alum!failed!to!reproduce!this!β8cell!
preservation!with!no!significant!improvement!in!C8peptide!levels!after!12156!or!15!months139.!
Potential! reasons!for!the!disappointing!results!of! later!trials!have!again!called! into!question!
the! limitations! of! extrapolating! from! animal! models! and! also! the! optimal! timing! of!
intervention.! For! ASI! earlier! intervention!may! be! necessary! as! by! clinical! presentation! the!
disease! is! already!well! established!and! therefore! the!presumed!mechanisms!of!ASI!may!be!





Diapep277! is! a! peptide! derived! from! heat8shock! protein! 60! (hsp60).! Despite! being! a!
ubiquitous! protein! the! peptide! was! found! to! be! an! autoantigen! linked! to! β8cell! secretory!




6! months119.! This! showed! β8cell! preservation! with! mean! C8peptide! concentrations! from!
glucagon!stimulation! reduced! in! the!placebo!group!but!maintained! in! the!Diapep277!group!
(0.26!vs.!0.93nmol/l,!p=0.039).!
Enzyme8linked! immunosorbent! spot! (ELISPOT)! assays! of! T8cell! cytokine! release! in* vitro! 10!
months!after!treatment,!revealed!that!when!using!hsp60!compared!to!peptide!p277!as!the!in*







A! further! phase! II! study! in! a! paediatric! population! failed! to! duplicate! the! outcome! of!
preserved!β8cell! function,!or! show!evidence!of! improved!glycaemic! control159.!A! large8scale!




into! question! and! the! article!was! retracted!due! to! concerns! about! serious!misconduct! and!
data!manipulation161.!Results!are!now!awaiting!independent!third8party!analysis.!
1.6.4 Proinsulin'C19$A3'
Proinsulin!C198A3! (PI!C198A3)! is!an!HLA:DR4* (DRB1*0401)! restricted!18!amino!acid!peptide!
with!the!amino!acid!sequence!of!GSLQPLALEGSLQKRGIV!(Fig!4),!which!matches!the!residues!
from! position! 19! on! the! C8peptide! chain! of! proinsulin! to! position! 3! of! the! A8chain.! Its!
relevance!as!an!autoantigen! in!Type!1!diabetes!was!supported!by! its!presence! in!a!panel!of!
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regulatory! IL810! responses! in! control! individuals75.!As!with!previous! studies! in! allergy,! as!PI!
C198A3! was! now! identified! as! a! target! epitope,! its! use! in! ASI! would! be! aiming! to! induce!










did! not! progress! with! subsequent! injections.! There! was! no! development! of! anti8peptide!
antibodies!or!consistent!change!in!anti8GAD!and!anti8IA82!antibodies.!!!!!
T8cell! cytokine! responses! were! evaluated! by! ELISPOT! assays! performed! by! the! laboratory!
blinded!to!subject!treatment!allocation!at!0,!3!and!6!months.!No!induction!of!IL84,!IL85!or!IL8





PIT! would! work! via! mechanisms! inducing! C198A38specific! CD4! IL810! secreting! cells! and/or!
deletion! or! suppression! of! pro8inflammatory! IFNγ producing! C198A38specific! cells.! Such!
favourable! responses! were! assessed! prior! to! unblinding! of! data.! Each! peptide! treatment!






(28%)! compared! to! the! higher! dose! (6%)! (Figure! 6).! However! these! responses! were! not!
sustained! after! withdrawal! of! the! peptide.! Interestingly! there! was! a! small! but! significant!
improvement!in!glycaemic!control,!shown!by!a!fall!in!HbA1c!by!0.23%!(95%!CI!80.42!to!80.03,!
p=0.02),! however! as! a! stand8alone! measurement! without! correlating! other! metabolic!
indicators!such!as!insulin!dose!and!within!a!small!study!this!HbA1c!fall!should!be!interpreted!
with!care.!!
Figure' 6:' Favourable' responses' seen' in' seen' in' ELISPOT' assay' during' phase' I' trial' of'
proinsulin'C19$A3'peptide.'From'Thrower'et'al117.'''
Graphs*show*ELISPOT*IL:10*and*IFN:ɤ*responses*to*peptide*at*0,*3*and*6*months*measured*by*

















Thrower! et! al.117! established! safety! of! PI! C198A3! PIT! in! long8standing! T1D! subjects! with!
evidence! pointing! towards! improved! efficacy! with! lower! doses.! Ultimately! use! of! immune!
interventions! would! target! individuals! at! or! even! before! diagnosis! in! order! to! maximise!
potential! for! salvage! of! β8cell! mass.! Should! such! therapies! risk! disease! progression,! newly!
diagnosed!patients!would!also!suffer!the!potential!loss.!The!MonoPepT1De!trial!was!designed!
to! examine! PI! C198A3! safety! in! a! newly! diagnosed! patient! cohort! who! exhibited! peak!
stimulated!C8peptide!levels!>200pmol/l.!This!level!was!established!by!the!DCCT47!as!clinically!
relevant! in!prevention!of! long8term! complications.! It! also! introduced!a!placebo!arm,!which!
was!lacking!in!the!phase!Ia!trial.!!
1.7.2 Trial'design'
The! MonoPepT1De! trial! was! a! multicentre! randomised,! double8blind,! placebo! controlled!
phase! 1b! trial! to! primarily! assess! the! safety! of! intradermal! administration! of! proinsulin!














• Diagnosis! of! Type! 1! diabetes!within! the! last! 100! days! (dated! from! the! first! insulin!
injection).!!
• Possession!of!*0401*allele!at!the!HLA:DRB1*gene!locus!!
• At! least! one! positive! islet! cell! autoantibody! (i.e.! anti8GAD65,! antibodies! to!
insulinoma8associated!antigen82!(IA82)!or!zinc!transporter!8!(ZnT8)).!!





• Females! who! are! pregnant,! breast8feeding! or! not! using! adequate! forms! of!
contraception.!!
• Use! of! immunosuppressive! or! immunomodulatory! therapies,! including! systemic!
steroids!within!1!month!prior!to!randomisation!and!any!monoclonal!antibody!therapy!
given!for!any!indication.!!





• Recent! subject’s! involvement! in! other! research! studies! which,! in! the! opinion! of!
investigators,! may! adversely! affect! the! safety! of! the! subjects! or! the! results! of! the!
study.!!
• Subjects! should! not! have! had! immunisations!with! live! or! killed! vaccines! or! allergic!
desensitisation!procedures!less!than!1!month!prior!to!their!first!treatment.!!
1.7.3 Primary'endpoint''
• Assessment!of! the!safety!of!PI!C198A3!peptide!administration! in!subjects!with!new8
onset!Type!1!diabetes.!!
1.7.4 Secondary'endpoints''
• Change! in! stimulated! C8peptide! production! at! 12,! 24,! 36! and! 48! weeks! versus!
baseline!and!between!groups.!!
• Change! in! level! or! quality! of! T! lymphocyte! biomarkers! of! β8cell! specific! immune!
response!at!12,!24,!36!and!48!weeks!versus!baseline!and!between!groups.!!
• Change! in! level! or! quality! of! islet! cell! autoantibody! biomarkers! of! β8cell! specific!
immune!response!at!12,!24,!36!and!48!weeks!versus!baseline!and!between!groups.!!
• Change! in! glycated! haemoglobin! (as! measured! by! %! HbA1c! levels),! daily! insulin!
usage,!and!mean!amplitude!of!glucose!excursions!at!12,!24,!36!and!48!weeks!versus!
baseline!and!between!groups.!!
• Changes! in! the! Hypoglycaemia! Fear! Survey! (HFS),! and! Diabetes! Treatment!
Satisfaction!Questionnaire!(DTSQs)!scores!at!3,6!and!12!months!and!ADDQoL!(Audit!





involves!blood! sampling! for!HLA*DRB1*0401! genotyping!and!autoantibody! testing! for!GAD,!


































β! polypeptide! chains! linked! by! disulphide! bonds.! These! αβ8TCRs! are! responsible! for! HLA8
restricted! antigen! recognition! through! interaction! with! peptides! presented! by! MHC!
molecules! on! antigen! presenting! cells.! In! order! to! allow! responses! to! a! wide! range! of!
pathogenic!molecular!signals,!humans!are!estimated!to!have!a!potential!αβ!TCR!diversity!of!
approximately!101381016!TCR!post!thymic!selection162,163.!This!huge!repertoire!is!formed!by!the!




segments,! in! combination! with! random! nucleotide! additions! and! deletions! to! segment!
junctions.! Within! the! α! and! β! chains! are! 3! hypervariable! complementarity! determining!
regions!(CDR).!CDR3,!formed!through!the!recombination!of!the!D!and!J!regions,! is!the!main!
recognition! site! for! processed! antigen.! Self8reactive! T8cells! undergo! negative! selection!
centrally! within! the! thymus,! however! those! that! escape! this! regulatory! step! can! lead! to!
autoimmune!disease.!Although!CDR3! regions!are! formed!by! chance! combinations,!bias! can!




In! NOD! mice! thymically! derived! nTreg! cells! were! found! to! show! a! lower! diversity! than!
controls!with!shortening!of!the!CDR3!region164.!Study!of!the!NOD!mouse!response!to!a!GAD65!
derived!peptide!revealed!a!public! response!using! the!Vβ4,!Dβ2.1!and! Jβ2.7!gene!segments,!
with!a!shared!CDR3!motif165.!An!EAE!mouse!model!examined!with!spectratyping!of!the!CDR3!
region!of! the!β!TCR!chain!revealed!the!presence!of! two!public!clonally! restricted!subsets! in!
response!to!a!MBP!epitope!Ac189,!one!linked!to!disease!onset,!which!could!transfer!disease!
to! naïve! recipients,! and! one! to! recovery166.! Similarly! another! group!was! able! to! identify! a!
CD4+!Treg!clonotype! in!EAE!mice! linked! to! recovery167.!Using!another!EAE!mouse!model,! it!
was! shown! that! expansion! of! TCR! diversity!with! epitope! spreading! is! linked! to! relapses! of!
EAE,!not!present! in!terminal!deoxynucleotidyl! transferase!(TdT)!knock8out!mice!who!have!a!
reduced!diversity!of!the!CDR3!region168.!!!!!
Using! high8throughput! screening! (HTS)! directed! at! islet8infiltrating!memory! CD4+! T8cells! in!
pre8diabetic! and!diabetic!NOD!mice,! distinct! unique!monoclonal! expansions!were! found! to!
dominate!the!islet!infiltrating!CD4+CD44high!TCRβ!repertoire!in!individual!diabetic!mice169.!Of!
these! expansions! a! number! were! shared! with! the! non8diabetic! mice,! which! the! authors!
suggest! may! be! due! to! pathogenic! clonotypes! being! resident! in! pancreas! before! disease!










involving* different* splicings* of* the* germline* V* (variable;* highlighted* in* blue),* J* (joining;*
highlighted*in*green)*and*D*(diversity;*highlighted*in*red)*β:chain*gene*segments*and*random*
nucleotide* additions* (no* highlight),* produce* the* same* nucleotide* sequences.* B.* The* second*
level*of*convergent*recombination*involves*multiple*nucleotide*sequences*encoding*the*same*
amino:acid* sequence.* Protein* sequences* with* amino* acids* in* the* V(D)J* junction* that* are*
encoded*by*many*codons*can*be*encoded*by*many*different*nucleotide*sequences.*C.*The*third*
level* of* convergent* recombination* is* at* the* level* of* the* TCR* repertoire,*where* some* of* the*
amino:acid* sequences* conform* to* an* amino:acid* motif.* In* this* particular* case,* the* ‘XGGX’*
amino:acid* motif* (where* X* denotes* any* amino* acid)* is* facilitated* by* strings* of* guanines*







diabetes! used! quantitative! PCR,! coamplification! with! radiolabelled! primers! and! liquid!
scintillation! in! 3! pedigrees171.! This! showed! there! were! no! significant! differences! in! the!
peripheral! repertoire! between! T1D! patients! and! their! unaffected! siblings! and! parents!
including! a! pair! of! discordant! monozygotic! twins.! This! was! echoed! in! another! study! of!





disease,! consideration! would! have! to! be! given! to! the! limitations! in! the! resolution! of! such!
techniques!in!whole!CD4/CD8!subsets!from!peripheral!blood.!!
Identification! of! TCR! clonotypes! in! human! pancreatic! islets! from! an! individual! recently!
diagnosed!with!T1D!showed!a!diverse!repertoire!of!islet!infiltrating!T8cells!consisting!of!Vβ1,!
Vβ7,!Vβ11,!Vβ17,! and!Vβ22! families,!within!which! there!was! a!biased!amino!acid!usage173.!
One!of!these!Vβ22!clonotypes!identified!could!be!traced!back!into!the!spleen!and!peripheral!
blood.!Until! recently!many! studies!have!used!older! technologies! to!analyse!TCR! repertoire.!
These!technologies!are!reviewed!by!Miles!et!al174.!Limitations!on!resolution!of!repertoire!are!
a! concern! with! older! methods! such! as! spectratyping! where! quantitative! measures! of! TRV!
gene!usage!are!limited!to!the!range!of!CDR3!length!variations!and!affected!by!variance!in!PCR!
efficiencies.! In! flow! cytometry! limitations! occur! as! not! all! Vα! and! Vβ!monoclonal! antibody!
fluorochrome!stains!are!available.!
Research!has!been!sparse!in!the!field!of!effects!of!PIT!on!TCR!repertoire,!although!one!study!
demonstrated! an! increase! in! TCR! diversity! using! spectratyping! of! CDR3! regions! of! a! Tr1!
population!in!those!treated!with!a!sublingual!multiple!epitopes!of!Cry!j!1!and!Cry!j!2,!major!
Japanese!cedar!pollen!allergens,!to!treat!pollinosis111.!
With! technologies! for! TCR! sequencing! continually! expanding,! HTS! is! allowing! ever! deeper!
analysis! of! TCR! diversity175,176! and! may! allow! identification! of! pathogenic! T! cell! receptor!
motifs!or!clonotypes!or!shifts!in!T8cell!populations.!Comparing!traditional!Sanger!sequencing!
with!HTS!such!as!the!Roche®!454!pyrosequencing!technology,!HTS!allows!a!higher!sensitivity!
sequencing! at! a! greater! depth! with! a! less! labour! intensive! methodology! and! with! the!
incorporation! of! parallel! sequencing! through!multiplexing,! the! costs! are! significantly! lower!
per!sample.!Another!HTS!method!using!the!multiplex!solid!phase!PCR!and! Illumina!genome!
analyser!technology,!was!able!to!sequence!tens!of!millions!of!TCRs!from!a!single!sample!with!
the! sensitivity! to!pick!out!extremely! rare! clones!doped! into! samples! at! a! frequency!of! 1! in!
100,000177.!!
Clonal!diversity!was!examined!in!T1D!using!HTS!exploring!CD4+!T8cells!presenting!markers!of!
early!activation! (CD69+/CD154+)!post! in*vitro! stimulation!with!an! islet!antigen! IA82752–775!or!
influenza! HA! peptide178.! Interestingly! HA! and! β8cell! epitope! specific! T8cell! total! numbers,!
clonotype! frequency! and!diversity!were! similar.! This! finding! contrasted!with!previous!work!










shared! between! individuals! however! the!αβ! pairing!was! always! unique.! These! findings! are!
discussed! further! in!6.4.3.!Developing! technologies! link! single! cell!α!and!β! sequencing!with!
transcriptome!analysis,!through!qPCR180!and!more!recently!single!cell!RNAseq181–183,!allowing!
more! in8depth! information! of! α! and! β8chain! clonotype! pairing! as! well! as! informing! on!
functional!phenotypes184!
1.9 Gene'expression'studies'
With! array! technologies! expanding! and! becoming! more! cost! effective,! gene! expression!
studies! have! become!powerful! and!widespread.! Such! studies! offer! an! insight! into! complex!
genetic! relationships! linked! to! disease8state! and! can! be! used! to! identify! “key! players”! in!
disease,!which! in! turn! can! focus!biomarker!discovery!and! therapy! targets.!Whilst! there!are!
studies! of! gene! expression! changes! within! islets185–188,! these! studies! are! impeded! by!
difficulties!in!obtaining!T1D!islet!samples,!which!can!vary!in!age!of!onset!and!disease!duration!
and! methods! of! islet! isolation! can! effect! cytokine! expression186.! In! T1D,! HLA! class! I!







Focusing! on! T8cell! specific! gene! expression! changes! can! pinpoint! immune8related!
dysregulation.!In!the!NOD!mouse!differential!gene!expression!was!seen!in!genetic!pathways!
(Clec16a,*Dlk1,*Rnls,*Sh2b3,*and*Zac1)!under! IL82!and! induction!of!Ctla4,*Foxp3,* Il2,*Ptpn22,*
Sh2b3,*and*Zac1!induced!by!TGF8β!signalling!in!T8cells189.!Orban!et!al.190!isolated!unstimulated!
CD4+! T8cells! from! newly! diagnosed! T1D! subjects! (less! than! 6! month! duration)! for! gene!









for! pathways! controlling! cellular!metabolism! and! survival,! including! endoplasmic! reticulum!
and!oxidative!stress!(e.g.!induction!of!HIF1A,*DDIT3,*DDIT4,!and!GRP78)!which!was!correlated!
to! glycaemic! control! in! the! first! year! after! diagnosis193.! This! is! an! important! consideration!
when!examining!treatment8linked!gene!expression!after!the!onset!of!dysglycaemia.!




















































































































































































































































models123,203! and! human! studies202.! In! a! small! study! of! lupus! patients! Sthoeger! et! al.202!
compared!a!tolerogenic!peptide!hCDR1!(n=5)!to!a!placebo!(n=4)!administered!weekly!for!26!
weeks.!Peptide!treatment!was!associated!with!downregulation!of!IL81β,!TNF8α,!IFN8γ,!and!IL8















































(PD81)! seen! however! cells! expressing! PD1! surface! markers! increased! in! number! following!
PIT203.!
Gene! expression! assays! such! as!microarray! provide! a! snapshot! of! a! biological! system! at! a!
particular!time!point!under!certain!conditions.!The!examples!above!illustrate!the!complexities!
of!gene!expression!studies!in!heterogeneity!and!expanse!of!results!available,!the!importance!
of! study! design! in! interrogation! of! relevant! genetic! changes! and! the! question! of!




source! of! differentially! expressed! genes! from! the! constituent! cell! subsets.! Pinpointing! this!
may! involve! isolating! or! stimulating! of! cell! subsets,! the! process! of! which! could! alter! gene!
expression!artificially.!Whilst!there!have!been!some!limited!data!on!gene!expression!changes!
in!PIT,!this! is!mainly! in!mouse!models!or!using!limited!clinical!cases.!One!of!the!aims!of!this!










3. Present!and!examine!changes! in!TCR!clonotypes!and!gene!expression!microarray! in!









(FCS)! was! purchased! from! Invitrogen! Life! technologies! (Paisley! UK).! Serum! was! heat!
inactivated!by!agitated!incubation!at!56oC!in!a!water!bath!and!aliquots!were!stored!at!820oC.!
Prior!to!use,!aliquots!of!serum!were!defrosted!and!added!to!culture!medium!before!storage!






Serum! islet! cell! autoantibody! titres! for! IA82,! ZnT8! and!GAD!were! analysed! using! ELISA! kits!
(RSR,!Cardiff,!UK),!performed!by!the!Diabetes!Research!Network,!Wales!Laboratory.!
2.3 C$peptide'assays'
Serum! C8peptide! levels! were! analysed! using! a! two8site! chemiluminescent! assay! (Invitron,!










were! diluted! 1:1! with! RPMI! complete! medium.! Diluted! blood! was! layered! onto!






for! 10min.! Resulting! PBMCs!were! then! re8suspended! in! fresh! RPMI! complete!medium! and!











Cryopreserved! control! PBMCs! were! used! at! each! flow! cytometry! sort.! Control! cells! were!
isolated!from!a!haemochromatosis!donor!and!cryopreserved!as!set!out!in!section!2.6.!These!
were! removed! from! liquid! nitrogen! storage! and! transferred! on! ice! to! a! 37oC! water! bath.!
When! samples! appeared! partially! thawed! 0.5mL! of! RPMI! at! 37oC!was! added! drop8wise! to!





The! U8CyTech! T8cell! ELISPOT! assay! (U8CyTech! Biosciences,! Utrecht,! The! Netherlands)! was!
used! for! detection! of! antigen8specific! IL810! and! IFN8γ! production.! Fresh! PBMCs! were!
dispensed! into! 488well! plates! at! a! density! of! 2! ×! 106! in! 0.5!ml! in! complete! RPMI!medium!
supplemented!with!10%!(v/v)!human!AB,!with!the!addition!of!peptide!to!a!final!concentration!
of!10!µM!and! incubated!at!37°C,!5%!CO2,! tilted!by!5°.!Control!wells! contained!TC!medium!
with!an!equivalent!concentration!of!peptide!diluent!alone!(Dimethyl!sulfoxide!(DMSO)!Sigma!





AB! serum! was! added,! and! on! day! +2,! non8adherent! cells! were! re8suspended! using! pre8
warmed!TC!medium/2%!AB! serum,!washed,! brought! to! a! concentration!of! 106/300!µl,! and!
100!µl!dispensed! in!triplicate! into!wells!of!968well!ELISA!plates!(Nunc!Maxisorp;!Merck!Ltd.,!
Poole,! United! Kingdom)! pre8blocked!with! 1:10! blocking! buffer! in! PBS! and! pre8coated!with!
monoclonal!anti–IFN8γ!or!anti–IL810!antibody.!After!capture!at!37°C,!5%!CO2!for!16818!hours,!
cells! were! lysed! in! ice8cold! water,! plates! washed! in! PBS/Tween! 20,! and! spots! developed!




















C13832! 10!mg/!mL! 1!µL!(10!µg)! Thermo!Scientific!Loughborough,!UK!
C228A5! 10!mg/!mL! 1!µL(10!µg)! Thermo!Scientific!Loughborough,!UK!
IA82!752875! 10!mg/!mL! 1!µL!(10!µg)! Thermo!Scientific!Loughborough,!UK!
IA82!709836! 10!mg/!mL! 1!µL(10!µg)! Thermo!Scientific!Loughborough,!UK!
IA82!853872! 10!mg/!mL! 1!µL!(10!µg)! Thermo!Scientific!Loughborough,!UK!








Proinsulin' (PI)' C19$A3' peptide! (GSLQPLALEGSLQKRGIV)! prepared! to! Good! Manufacturing!
Practice!standards!was!supplied!by!Novo!Laboratories! (Leicester,!UK)!as! lyophilised!peptide!
and!stored!at!820oC.!The!peptide!was!>!95%!pure,!endotoxin8free!and!showed!no!toxicity! in!
formal! testing! in! two! species! (guinea8pigs! and! mice).! Stocks! were! diluted! to! 10mg/mL! in!
phosphate! buffered! saline! (PBS,! Invitrogen! Life! Technologies,! Paisley! UK).! Once! diluted!
aliquots!were!stored!at!4oC.!!
Haemagglutinin' (HA' 306$318)' (PKYVKQNTLKLAT)! was! purchased! from! Thermo! Scientific!
(Loughborough,!UK)!as! lyophilised!peptide!of!>95%!purity,!and!stored!at! 820oC.!Stocks!were!
diluted!to!10mg/mL! in!phosphate!buffered!saline! (PBS,! Invitrogen!Life!Technologies,!Paisley!
UK).!Once!diluted!aliquots!were!stored!at!4oC.!!
Staphylococcal'Enterotoxin'B' (SEB)'was!purchased! from!Sigma!Aldrich! (Dorset,!UK).! Stocks!
were! diluted! to! 1mg/mL! concentration! in! phosphate! buffered! saline! (PBS,! Invitrogen! Life!
Technologies,!Paisley!UK)!and!stored!at!820oC.!Once!diluted!aliquots!were!stored!at!4oC.!!
Pediacel®,! a! penta8vaccine! consisting! of! purified!diphtheria! toxoid,! purified! tetanus! toxoid,!
acellular! pertussis! vaccine,! inactivated! poliovirus! and!Haemophilus* influenzae!type! b!
polysaccharide,!was!obtained!from!Sanofi!Pasteur!MSD!(Berkshire,!U.K.)!and!used!at!1!μL/mL.!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
Anti$CD28'and'anti$CD40'monoclonal'antibodies:'details!of!these!antibodies!are!provided!in!























Target! Isotype! Clone! Fluorophore! Supplier!


























The* table* states* the* antibody’s* target* antigen,* isotype,* clone* and* supplier.* APC:*






expression! 205,206! with! the! addition! of! a! co8stimulatory! signal! from! anti8CD28! antibody! .!
Samples!were!collected!from!trial!patients!at!baseline,!month!1,!2,!4!and!5!with!captured!cells!























PBMCs!were! isolated! from!whole!blood!using!density8gradient!centrifugation!as!outlined! in!
section!2.5.!Cells!were!re8suspended!at!a!concentration!of!4x106!per!mL! in!complete!RPMI.!
Cells!were!cultured!with!anti8CD28!antibody!(1μg/mL)!and!anti8CD40!antibody!(1μg/mL)!with!






Cells! were! harvested! using! warmed! complete! RPMI! supplemented!with! 2%! AB! serum! and!
washed!twice!in!cold!PBS!at!4oC!centrifuging!for!10min!at!1400rpm.!ViVid!was!used!following!
manufacturer’s! instructions! to! stain! dead! cells! before! a! further! wash! in! cold! PBS! at! 4oC,!
centrifuging! for! 10min! at! 1400rpm.! Following! this! cells! were! stained! using! fluorochrome!






























Once! mastermix! was! made! up! it! was! briefly! vortexed! and! centrifuged! to! avoid! adding!
aggregates!to!cells.!Following!this!the!volumes!stated!were!added!to!each!sample.!Cells!were!
then! incubated! at! 4oC! for! 20mins! whilst! on! a! MACSmixTM! tube! rotator! (Miltenyi! Biotec,!
Surrey,! UK),! before! being! washed! twice! in! cold! PBS! at! 1400rpm! for! 5min! at! 4⁰C! and! re8
suspended! for! Fluorescence8Activated! Cell! Sorting! (FACS)! in! cold! FACS! buffer! (5%! FCS!
(Invitrogen)!in!PBS).!
2.9.2 Cell'sorting'




for! CD3/CD4/CD69/CD154! positivity! and! sorted! for! gene! expression! studies! (section! 2.10)!
and/or! TCR! sequencing! (section!2.11).! In! the! case!of! TCR! sequencing,! samples!were! sorted!
into! 1.7mL! RNase8free! microcentrifuge! tubes! containing! 350μL! RNeasy! (RLT)! buffer! and!









The*plots* illustrate*(A)* identification*of*a* lymphocyte*group*and*exclusion*of*doublets*on*(B)*







2.9.3 Cloning' of' T$cells' by' single' cell' sorting' populations' from' Pediacel®'
stimulated'PBMCs'




Systems,! Stockport,! United! Kingdom).! Cells! were! incubated! at! 37oC! and! maintained! in! X8
VIVO®! supplemented! with! 5%! AB! serum! and! 5%! Cellkines,! reducing! the! concentration! of!
Cellkines! by! half! every! 5! days.! Clones! underwent! alternate! rounds! of! expansion! every! 2!
weeks! with! irradiated! mixed! donor! or! matched! donor! PMBCs! (1.5x105! cells),! containing! 4!




proliferation,! antigen! specificity! of! clones! was! tested! under! 4! conditions:! i.! Clone! only!
(negative! control),! ii.! Clone! and! HLA!matched! PBMCs,! iii.! Clone,! HLA!matched! PBMCs! and!
Pediacel! and! iv.! Clone! and! anti8CD3! anti8CD28! dynabeads! (Life! Technologies,! Paisley,! UK)!
(polyclonal!stimulus/positive!control).!At!48!hours!of!culture,!supernatants!were!removed!for!
cytokine! analysis! and! 0.5!mCi/well! tritiated! thymidine! [3H]! (PerkinElmer,! Buckinghamshire)!
was! added.! The! cells! were! harvested! 18! hours! later! using! a! MicroBeta! Trilux! machine!
(PerkinElmer)!to!assess!3H8Thymidine!incorporation!as!a!measure!of!proliferation.!IFN8γ!levels!




For! the! gene! expression! analysis,! SuperAmpTM! lysis! buffer! (Miltenyi! Biotec,! Bergisch!





than! 1μL,! 6.4μL! of! prepared! SuperAmpTM! buffer! was! added! directly! to! the! sample.! For!
samples!with!a!volume!of!between!1μL!and!200μL!(up!to!10,000!cells),!cells!were!pelleted!by!








SuperAmp! RNA! amplification! was! performed! according! to! an! undisclosed! procedure! by!





for! cell! number.! Amplified! cDNA! samples! were! quantified! using! the! ND81000!
Spectrophotometer! (NanoDrop! Technologies,! Wilmington,! DE,! USA).! cDNA! integrity! was!
checked! using! a! Agilent! 2100! Bioanalyzer! platform! (Agilent! Technologies,! Santa! Clara,! CA,!
USA).!The!results!of!the!bioanalyzer!run!were!visualised!via!gel!images!and!the!integrity!of!the!




A! total! of! 96! samples!were! sent! for!microarray! analysis! on!Agilent!Whole!Human!Genome!
8x60K!v2!microarray!format!using!a!18color!approach.!250!ng!of!each!of!the!cDNAs!were!used!
as!template!for!Cy3!labeling!which!was!performed!according!to!Miltenyi!Biotec’s!undisclosed!
protocol.! The! Cy38labeled! cDNAs!were! hybridized! overnight! (17! hours,! 65°C)! to! an! Agilent!
Whole! Human! Genome! Oligo! Microarrays! 8x60K! v2! using! Agilent’s! recommended!
hybridization!chamber!and!oven.!No!adjustment!was!made!for!cell!number!at! this!stage.! In!
order!to!avoid!batch!effects,!samples!were!randomised!across!13!slides!each!with!8!samples!
in! 4! batches,! to! assign! samples! randomly! across! slides,! positions! and! batches.!Microarrays!
were! washed! once! with! Agilent! Gene! Expression! Wash! Buffer! 1! for! 1! minute! at! room!
temperature!followed!by!a!second!wash!with!preheated!Agilent!Gene!Expression!Wash!Buffer!
2!at!37oC!for!1!minute.!Cy3!fluorescence!signals!of!the!hybridised!microarrays!were!detected!




template8switch! anchored! reverse! transcription8polymerase! chain! reaction! (RT8PCR)! for!
unbiased!analysis!of!TCR!populations.!The!polyA!tails!of!RNA!are!bound!by!oligo!(dT)!primers!
(5’! CDS)! and! a! complementary! cDNA! strand! is! generated! by! SMARTscribe! reverse!
transcriptase! (RT).! SMARTscribe! RT! exhibits! terminal! transferase! activity! that! adds! 385!
residues! to! the!3’!end!of! the! first! strand!cDNA.!This!elongated!region!allows!binding!of! the!
SMARTerIIA!oligonucleotide.!This!acts!as!a!switching!mechanism!for!the!RT!onto!the!5’!end!of!
the! RNA! transcript,! followed! by! rapid! amplification! of! cDNA! ends! (5’RACE).! Two! rounds! of!
nested!PCR! follow! cDNA! synthesis,! initially! using! a! universal! primer!mix! (UPM)! to! bind! the!




nested! within! the! original! cDNA! product.! These! processes! are! summarised! in! Figure! 12!
below.! A! negative! control! is! introduced! at! each! step.! This! allows! visualisation! of!
contamination!at!gel!electrophoresis!and!tracking!to!point!of!introduction.!Once!PCR!rounds!
are! complete,! amplicons! can! be! ligated! into! a! cloning! vector! that! is! transformed! into!
competent!E.* coli.!Upon! culture! blue/white! colony!discrimination! can! identify! recombinant!































































































RNA! was! extracted! from! sorted! cells! using! the! RNeasy! Micro! Kit! (Qiagen,! Limburg,!
Netherlands)! using! manufacturer’s! protocol.! Samples! were! defrosted! on! ice! and! all! steps!
were!carried!out!at!room!temperature.!One!volume!(350μL)!of!70%!molecular!biology!grade!




500μL! RPE! buffer! to! the! spin! column! and! centrifuged! again.! 500μL! of! 80%! ethanol! was!




cDNA! synthesis! was! performed! using! the! SMARTerTM! RACE! cDNA! amplification! kit!























60μL! of! Tricine! EDTA.! Briefly,! a! 2:1! ratio! of! NT! binding! buffer! was! added! to! each! sample,!
which! was! then! transferred! onto! a! Nucleospin! column! to! bind! DNA! to! membrane! and!
























5x!Phusion!HF!Buffer! 5x! 10.0μL! 1x!
dNTP!mix! 10mM! 1.0μL! 0.2mM!
UPM!(Forward!Primers)! 10x! 5.0μL! 1x!
TRBC8R2!(Reverse!Primer)! 10μM! 1.0μL! 0.2μM!
5’RACE!cDNA!product!(or!negative!control)! 8! 5.0μL! !
Phusion!polymerase!! 2000!
units/mL! 0.5μL! 1!unit/50μL!







Initial!denature! 98! 30! !
















This! step! was! carried! out! using! the! Minelute! PCR! purification! kit! (Qiagen,! Limburg,!
Netherlands)! as! per!manufacturer! protocol!with! the! further! addition!of! a! negative! control.!
Briefly,! 5! volumes! of! binding! buffer! PB!were! added! to! the! PCR! reaction,! placed! onto! spin!
column!and!centrifuged!for!1min!at!13,000rpm.!Bound!DNA!was!washed!with!750μL!of!buffer!





Multiplex! Identifier! (MID)! labelled! primers! were! incorporated! at! this! stage.! These! were!
designed! to! contain! a! unique! 108base! barcode! or! identifier! sequence,! followed! by! a! ‘CA’!
linker!between!barcode!and!the!TRBC8specific!sequence!(see!Table!11).!MID!sequences!were!
provided!by!Roche! (Hertfordshire,!UK).! Primers!were! synthesised!with! salt8free!purification!







































subsequent! clean8up!was! inadequate! to! provide! adequate! substrate! for!MID! validation! by!
real8time!PCR!experiments.!Therefore!a!previously! sequenced!TCR!β8chain!was!chosen!as!a!
substrate!and!underwent!A’tailing,!ligation,!transformation!into!E.*Coli!and!culture!(following!
methods! described! in! sections! 2.11.8! to! 2.11.11).! Following! culture! the! plasmid!
minipreparation! was! performed! (section! 2.11.12).! Serial! dilutions! of! the! plasmid! miniprep!
(1:10,! 1:100,! 1:1000,! 1:10,000,! 1:100,000)! provided! the! cDNA! for! real8time! PCR.! Reactions!
were! assembled! in! triplicate! as! summarised! in! Table! 12,! using! SYBR!Green!mastermix! (Life!
Technologies,! Paisley! UK).! Reactions! were! carried! out! on! Applied! Biosystems! 7900HT!
Sequence!Detection! System!under! conditions! in! shown! in! Table! 13! and! analysed!using! the!
associated! software! (version! 2.3).! Efficiency! of!MID! primers!was! calculated! using! Ct! values!
from!using!the!equation:!Efficiency!(%)!=!10(81/slope)81.!








SYBR!Green!Mastermix! 2x! 10μL! 1x!
5’RACE!(Forward!primer)! 10μM! 0.4μL! 0.2μM!
MIDX8TRBC8R! 10μM! 0.4μL! 0.2μM!
cDNA! ! 0.5μL! !











! 50! 120! !
Activation! of! polymerase! within!
mastermix!
95! 600! !
Denature! 95! 15! 40!
Anneal!and!extend! 60! 60! 40!
'
Once! relative! efficiency! of! MID8labelled! primers! had! been! assessed,! these! primers! were!









5x!Phusion!HF!Buffer! 5x! 10.0μL! 1x!
dNTP!mix! 10mM! 1.0μL! 0.2mM!
5’RACE!F!(Forward!primer)! 10μM! 1.0μL! 0.2μM!
MID!X8TRBC8R!(Reverse!Primer)! 10μM! 1.0μL! 0.2μM!
PCR!product!(or!negative!control)! 8! 4.0μL! !
Phusion!polymerase!! 2000!units/mL! 0.5μL! 1!unit/50μL!











Initial!denature! 98! 30! !















DNA! gel! stain! (Invitrogen)! was! added! at! a! concentration! of! 1:10,000! before! pouring! into!
moulds.!!
Second! round! PCR! products! and! negative! controls! were! run! alongside! a! 100bp! ladder.!
Products!of!~500bp!were!cut!out!for!extraction!and!negative!control!lanes!were!screened!for!
visible!contamination.!DNA!was!extracted!from!gel!slices!using!the!QIAquick!Gel!Extraction!kit!
(Qiagen,! Limburg,!Netherlands).!Briefly,!3!volumes!of!QG!buffer!were!added! to! the!gel!and!




13,000rpm.! A! further! centrifugation! step! to! dry! the! membrane! followed! for! 1min! at!
13,000rpm.! ! DNA! was! eluted! using! 10μL! of! buffer! EB.! At! this! stage! samples! continued! to!

















PCR!cDNA!!product! ! 8!μL! !
Taq!advantage!2!polymerase! 50x! 1.14μL! 5x!
Advantage!2!PCR!Buffer! 10x! 1.14μL! 1x!
dATP! 10mM! 0.456μL! 0.4!
















2x!Ligation!buffer! 2x! 7.5μL! 1x!
A’tailed!cDNA!product! 8! 4.0μL! 8!





























After! incubation!white!colonies!were! individually!picked!and!sent! for!Sanger! sequencing!by!
GATC®! Biotech.! TCR! sequences! were! then! processed! using! International! Immunogenetics!
Information!System®!(IMGT)!website.!
2.11.12 Plasmid'Minipreparation'
Following! incubation! of! transformation! reactions! (2.11.10)! plasmid!DNA!was! isolated! using!
the!QIAprep!Spin!Miniprep!Kit!(Qiagen,!Limburg,!Netherlands).!In!brief,!1.5ml!of!culture!broth!
was! transferred! to! an! eppendorf! tube! centrifuged! at! 9000rpm! at! room! temperature! for! 1!
minute,! the! supernatant!was! discarded! and! the! process! repeated.! 250μL! of! buffer! P1!was!
added!to!the!pellet!and!the!mixture!was!vortexed!until!homogenised.!250μL!of!buffer!P2!was!
added!and!mixed!thoroughly!by!inversion.!350μL!of!buffer!N3!was!added!and!again!mixed!by!
inversion.! The!mixture!was! centrifuged! at! 13,000rpm! for! 10mins! and! the! subsequent! clear!
supernatant! was! placed! onto! spin! columns! provided! in! the! kit.! The! column! was! spun! at!










TCR! data! was! received! in! FASTA! format! following! sequencing! using! Roche! 454! GS! FLX!
technology! via! Eurofins! MWG! Operon! (Ebersberg,! Germany).! FASTA! files! then! underwent!
high8throughput! analysis! via! the! Immunogenetics! Information! system! (IMGT/High! V8
Quest)208,209.!Subsequent!data!was!sorted! in!Microsoft®!Excel®! for!Mac!2011!(Version!14.4.8)!
to! allow! for! processing! data! through! KNIME! Analytics! Platform! (Version! 2.11.3,! Konstanz,!
Germany).! KNIME! data! was! further! analysed! by! a! biostatisician! using! R! language210! with!




analysed! using! D’Agostino! and! Pearson! omnibus! normality! testing.! Non8parametric! clinical!
data! underwent! log! transformation! was! performed! to! reduce! skewness! followed! by!
parametric!analysis.!Correlation!analysis!was!performed!using!Pearson!correlation.!Unpaired!
tests! were! used! to! compare! means! between! groups! (using! Welch’s! correction! if! unequal!











Optimisation! of! potential! β8cell! salvage! in! T1D! intervention! studies! relies! upon! narrow!
timeframes! from!diagnosis!as!set!out!by! Immunology!of!Diabetes!Society! (IDS)!guidelines72.!
From!a!patient!perspective,! the! impact!of! a! recent!diagnosis! of! a! chronic!disease! can!be! a!
significant!barrier!to!committing!to!clinical!research.!For!others!clinical!research!can!provide!a!
positive! focus! post8diagnosis.! Recruiting! a! young,! mainly! working,! adult! cohort! into! an!




1. Identification! of! patients! close! to! diagnosis,! consenting,! screening! and! recruitment!
into! the! study.! To! ensure! local! clinical! teams!were! aware!of! the! trial! I! coordinated!
presentations!to!my!peers!at!numerous!local!meetings,!targeting!diabetes!teams!and!
educational!meetings!for!diabetes!registrars.!
2. Regular! weekly! teleconferencing! with! the!MonoPepT1De! clinical! trial! management!
team! at! Cardiff! University,! representatives! of! each! site! and! our! own! local! sponsor!
representatives.!!!





6. Coordinating! blood! samples! from! trial! centres! for! processing,! including! managing!
priority!access!to!flow!cytometry!facilities!for!my!specific!research!projects.!!





Pathways! utilised! in! subject! identification! included! liaison! with! NHS! trusts! local! to! each!
centre,! local!research!networks!and!the!national!After!Diabetes!Diagnosis!REsearch!Support!





the! Diabetes! Research! Network! (DRN)! jointly! funded! by! Diabetes! UK! and! the! Juvenile!
Diabetes! Research! Foundation,! with! support! from! the! Department! of! Health! via! the! NIHR!
Clinical! Research! Network:! Diabetes! and! NIHR! Clinical! Research! Network:! Children.! The!
MonoPepT1De! study! was! also! promoted! via! supporting! charities,! and! national! media.! A!
























visits! per! month! with! 50,000! Facebook! members).! To! target! appropriate! patients! on! the!
website! details! were! published! on! Type! 1! or! newly! diagnosed! online! fora! and! electronic!
newsletters.! Subjects! then!expressed! interest! through!an!online! form,! self8reporting!details!
for!eligibility.!Twenty8one!enquiries!were! received,!out!of!which!11!users!wrongly! reported!















































































































































































































































































































































































































































































































































































Cardiﬀ'' 20' 60' 6' 42' 28' 57' 19' 5' 237' 81' 29.6' 6.2' 20.8'
London# 4# 11# 4# 7# 12# 45# 18# 13# 114# 76# 40.8# 17.1# 41.9#
Bristol' 1' 3' 1' 7' 2' 27' 10' 4' 55' 41' 34.1' 9.8' 28.6'
Newcastle' 1' 1' 0' 4' 0' 15' 9' 4' 34' 28' 46.4' 14.3' 30.8'























impact! of! the! diagnosis! of! T1D! was! highlighted! as! an! obstacle! to! enrollment.! The!
panel! felt! the! tight! timeframe! was! a! drawback,! as! subjects! would! have! a! greater!
inclination! to! consider! research! with! interventional! therapies! when! their! diagnosis!
was!more!established.!Only!36%! (4)!of! the!panel! (n=11)!would!have!agreed! to! trial!
screening! at! diagnosis! compared! to! 64%! (7)! who! would! agree! if! offered! the!
opportunity!once!the!diagnosis!was!well!established.! In!a!young!age!group,!work!or!










to! potential! research! candidates! considering! the! trial.! Such! support! could! be!
provided! formally! from!healthcare!professionals!or! via!volunteers!with!T1D!already!
engaged! in! research! through!a!“buddying”!system.!Alternatives!suggested!were! the!
creation! of! a! participant! community! either! within! the! trial! or! within! the! wider!
ADDRESS82!population.!Networking!through!social!media!was!felt!to!be!an!effective!
way!to!connect!those!requiring!support.!














o Potential! streamlining! of! trial! recruitment! by! combining! screening! for! a!






been! completed.! Patient! eligibility! through! the! screening! process! and! trial! retention! are!
summarised!in!Figure!16.!






























































GAD#posi5ve# 76%# 93%# 61%#
IA2#posi5ve# 46%# 67%# 51%#
ZnT8#posi5ve# 52%# 64%# 64%#









































GAD'posiJve' 76%' 93%' 61%' 64%'
IA2'posiJve' 46%' 67%' 51%' 73.8%'
ZnT8'posiJve' 52%' 64%' 64%' 70.5%'
AnJbody'negaJve' 17%' 5' 10%' 6.6%'
'
Figure'18:'Overview'of'screening'outcome'from'first'screening'visit.''
The* figure* illustrates* results* of* tests* of* autoantibody* and* genotype* testing.* *Out* of* the* 31*


































During! the! early! window! of! 1008days! post! diagnosis,! 96.4%! (n=27)! who! had! a! MMTT!
surpassed! the! threshold! of! 0.2pmol/mL.! Median! and! range! of! mean! AUC! of! C8peptide! at!
screening!was!0.58!(0.23882.805)!pmol/mL/min.!Mean!AUC!C8peptide!between!for!males!was!










































































































































































































































































































































































Homozygotes! for! HLA* DRB1*0401! had! higher! median! C8peptide! AUC! than! heterozygotes!









































to!World!Health!Organisation! criteria! (BMI!≥30kg/m2),!with!2!of! these! in! the!obese! class! II!
category!(BMI!≥35kg/m2).!There!was!a!stepwise!increase!in!C8peptide!levels!in!each!BMI!band!
(Table! 19,! Figure! 20.! Correlations! of! C8peptide! AUC! and! insulin! resistance! using! HOMA2!
(Homeostasis! model! assessment! 2)! analysis! were! considered! but! could! not! be! performed!
















































0%# 10%# 20%# 30%# 40%# 50%# 60%# 70%# 80%# 90%# 100%#
HLA#DR1*0401#posi7ve#
HLA#DR1*0401#nega7ve#
























1019! 36.7! 24! 648! 8! 8! 8! Yes! 2.56!
2031! 36! 30! 78! 8! 8! Aunt! and!Grandmother! Yes! 2.81!
2016! 30.7! 22! >2000! 8! 8! Sibling! Yes! 0.31!
2011! 30.2! 36! 202! 164! 18! Sibling! Yes! 1.73!
'






























of!unique!challenges.!Multiple!approaches!were!necessary! to! identify! relevant!subjects!and!
to!highlight!the!active!research!opportunity!open!to!these!individuals.!Traditional!media!were!
used! through! press! releases! in! combination! with! the! adoption! of! an! effective! online!
presence.!Such!approaches!have!also!been!successful!in!another!T1D!intervention!trial!of!IL82!
therapy213.! ! Initially! lower! than!predicted! screening! numbers! and! levels! of!HLA:DRB1*0401!
positivity! lead! to! delayed! completion! of! recruitment.! By! the! end! of! the! recruitment! the!
proportion! of!HLA:DRB1*0401! positive! patients! equalled! our! expectations,! suggesting! that!
the!initial!run!of!negative!results!was!a!statistical!abberation!which!normalised!with!greater!
numbers.!The!incorporation!of!the!ADDRESS82!register!into!our!screening!strategy!in!October!
2012! coincided! with! an! approximate! 28fold! increase! in! screening! (Figure! 14).! Further!
strategies!to!optimize!screening!rates!included:!!




• Linking!with!Diabetes!UK! (DUK)! and! Juvenile!Diabetes! Research! Foundation! (JDRF).!
DUK!and! JDRF!provided!additional! support!by! raising!awareness!of!our!work!within!





into! the! study.! There!were!methodological! and! logistical! restraints! on! suggestions,! such! as!
widening! the! age! or! time! frame! criteria! and! opening! up! weekend! appointments.!
Nonetheless,! as! a! direct! result! of! the! meeting,! a! “buddying”! system! for! individuals! was!
integrated!into!the!trial!to!provide!support!from!research8experienced!peers.!Ethical!approval!
was!obtained!to!allow!subjects!to!contact!enrolled!subjects!who!had!volunteered!to!“buddy”!






communication! between! subjects,! necessitating! a! more! structured! contact.! There! were!
important!ethical! considerations! regarding! the!use!of! social!media! for! communication!with!
and! between! patients,! in! regards! to! consent! and! anonymity.! In! addition! setting! up! and!
managing! these! systems! would! require! extra! staff! time.! Crucially! the! feedback! from! this!
panel! and! the! practical! experience! acquired! during! the! study! was! used! to! improve!
recruitment! throughout! the! trial! and! continues! to! positively! influence! the! design! of! local!
intervention!trials!planned!in!the!future.!!!!
With! 11%! of! eligible! referrals! being! excluded! as! they! would! have! exceeded! the! 100! day!
window! by! the! completion! of! screening,! this! study! emphasizes! the! time! constraint! on!
recruiting!soon!after!diagnosis.!A!significant!proportion,!35%!(76),!were!not!newly!diagnosed,!
many! of! these! being! self8referrals.! The! initiation! of! recruitment! via! ADDRESS82! was!
associated!with!a!significant!rise!in!screening!numbers!but!on!closer!analysis!other!strategies!
may!have! contributed! to! this! rise.!Despite!188! subjects!being! identified! via! the!ADDRESS82!
register!only!a!total!of!10!subjects!(5.3%)!from!ADDRESS82!were!screened,!with!3!proceeding!
to! randomization.! The! screening! figures! appear! low! in! view!of! high!potential! numbers! and!




consent! allowing! ADDRESS82! staff! to! pass! contact! details! to! the!MonoPepT1De! team.! This!
prolonged! process! added! pressure! to! screen! within! an! already! tight! window.! Local!
identification! of! subjects! frequently! allowed! face8to8face! discussion!with! a!member! of! the!
research! team,! which! was! not! possible! via! ADDRESS82! and! it! is! likely! that! a! personal!
introduction! to! the! study! led! to! a! higher! uptake.! Geographical! factors! were! likely! an!
additional! consideration! for! ADDRESS82! patients.! ! The! use! of! the! www.diabetes.co.uk!
commercial! website! gave! disappointing! results,! despite! potentially! far8reaching! exposure.!
Limited!details!of!the!trial!were!permitted!to!avoid!subjects!directly!contacting!the!team!and!





The! recruitment! centre! at! Guy’s! and! St.! Thomas’s! NHS! Trust! (GSTT),! London! recruited! the!
highest!number!of!subjects!with!good!retention!of!patients!through!the!trial.!I!attribute!this!
to!the!following!likely!explanations:!
• Research! team:! As! clinical! research! fellow! to! this! study! I! was! able! to! identify! and!
liaise! directly! with! patients! with! enough! dedicated! time! to! promote! the! trial! at!
different! levels,! and! ensure!wide! exposure! of! the! trial! locally.!My! prior! experience!
with! the! inpatient! and!outpatient! teams! facilitated! referrals.! Patients!were!able!on!
the! whole! to! have! one! direct! contact! point! for! queries,! which! allowed! a! more!
personal!approach.!
• Location:!GSTT!has!a!large!catchment!area!and!is!located!within!a!city!with!a!younger!
population! than! the! country! as! a! whole.! There! are! ADDRESS82! sites! and! potential!
referral!centres!are!clustered!around!London.!Good!transport! links!allowed!patients!
to!travel!further!for!visits.!
• Research! infrastructure:! Flexibility! with! facilities! and! staffing! allowed! us! to! offer!
earlier!appointment!times!so!patients!would!attend!before!work.!With!an!established!
research! history! in! immune! studies! some! clinicians! were! already! aware! of! the!
centre’s!ongoing! interests!and!patients!were!able! to! identify! the!centre! through! its!
public!profile.!!!!
The!total!number!of!subjects!passing!HLA*DRB1*0401!allele!screening!was!slightly!lower!than!
estimated,! with! 43.0%! (n=37)! being! positive,! all! of! whom! were! Caucasian.! Data! from! the!
South!West! newly! diagnosed! diabetes! Type! 1! collection! (SWENDIC)! showed,! of! 345! newly!
diagnosed! adults! recruited! since! 1999,! the! frequency! of! HLA* DRB1*0401! was! 52.4%!
(unpublished! data,! C.! Dayan).! In! control! populations! the! proportion! of! the! allele! HLA*
DRB1*0401!is!estimated!at!between!10.3825.1%214,215.!In!the!adult!onset!T1D!population!this!
is!higher!at!48%,!with!similar!levels!in!childhood!groups216.!This!correlated!well!with!US!data!
which! showed! 48.8%! of! T1D! subjects! displaying! the! allele217.! Unfortunately! false! negative!
results! for!HLA:DRB1*0401! in!our! screening!mistakenly!excluded! two! subjects! from! further!
screening.!!
Using!a!panel!of!four!autoantibodies,!GAD,!IA82,!IAA,!and!ICA!or!ZnT8,!only!2–4%!of!children!
are! autoantibody! negative! at! diagnosis218,! but! there! is! little! data! fully! comparable! to! our!




Vaziri8Sani!et!al.212!used! identical!screening!autoantibodies,!GAD,! IA82!and!ZnT8,! in!a!similar!
age! range! (15834! years)! within! a! Swedish! population! at! diagnosis.! Their! data! (Figure! 17)!
showed!less!antibody!negativity!(10%!versus!17%!in!the!MonoPepT1De!group)!and!less!GAD8
centric! responses! compared! to!our!group.!Differences! in!assay! techniques!may!account! for!
some!of!the!discrepancy.!The!assays!used!by!Vaziri8Sani!et!al.!were!radioligand8binding!assays!
(RBA)! compared! to! ELISA! in! MonoPepT1De! patients.! GAD! autoantibody! (RBA)! had! lower!
sensitivity! at! 86%! and! specificity! at! 93%,! compared! to! 92%! and! 98%! respectively! in!
MonoPepT1De.! ! Similarly! IA82! autoantibody! RBA! sensitivity! was! 66%,! specificity! 98%!
compared!to!rates!in!ELISA!of!72%!and!99%!respectively.!Higher!sensitivity!of!the!ELISA!assays!
does! not! explain! the! higher! antibody! negative! cohort,! however! our! age! range!was! slightly!
higher!and!both!autoantibody!negativity,!GAD!positivity!and! titre! rise!with!age219.!Although!
the! MonoPepT1De! group! was! homogeneously! Caucasian,! there! may! be! geographical!
variations!of!genotypes!between!the!UK!based!and!Swedish!populations! to!account! for! the!
differences!in!autoantibody!profiles.!The!inclusion!of!IA82!autoantibody!in!the!MonoPepT1De!
screening! panel! did! not! increase! positive! screening! outcome! over! GAD! and! ZnT8,! as! no!
patients!were!positive!for!IA82!antibody!alone!compared!to!3%!in!the!Vaziri8Sani!et!al.!data.!
Autoantibody! profile! at! diagnosis! has! been! linked! to! low! baseline! C8peptide,! with! the!
presence! of! GAD! antibody! linked! to! more! rapid! C8peptide! decline220,! however! these! data!
used!fasting!or!random!C8peptide!and!no!comparable!distinction!was!seen!at!baseline!in!the!
MonoPepT1De! dataset.! Interestingly! there! was! a! significant! negative! correlation! between!
ZnT8! autoantibody! titre! and! C8peptide! AUC! (Table! 19,! p=0.01)! within! this! adult! HLA:
DRB1*0401! population.! This! correlation! was! not! found! in! another! study! of! ZnT8! titres! at!
diagnosis!against!MMTT!stimulated!C8peptide221.!This!small!cohort!(n=21)!of!newly!diagnosed!
patients!was!not!HLA!screened!and!again!age!of!subjects! (mean!20.3!(12.2834.6)!years)!and!
use! of! an! alternative! immunoprecipitation! assay! (incorporating! a! dimeric! construct! to!




The! majority! (96.4%)! of! our! HLA:DRB1*0401! and! autoantibody! positive! subjects!






to! baseline! residual! β8cell! function! as! measured! by! mean! C8peptide! AUC! on! the! MMTT!
showed!that!fasting!and!peak!C8peptide!levels!had!the!strongest!relationship.!This!reiterates!
published! data! findings! showing! fasting! C8peptide! correlating! with! C8peptide! AUC! when!





population.! Correlates! of! β8cell! reserve! estimated! through! mean! C8peptide! AUC! are!
important! when! considering! future! surrogate! markers.! From! this! baseline! data! fasting! C8
peptide!appears! to!be!a! very! good! surrogate! for!mean!C8peptide!AUC!and!would!have! the!
advantage! of! negating! the! need! for! a! MMTT,! which! would! be! particularly! beneficial! in!
children.!Nevertheless!fasting!C8peptide!requires!further!validation!to! identify!a!comparator!











of! a! median! duration! of! 6.5! (2.3832.7! years)73.! The! benefits! of! this! test! are! its! non8
invasiveness,! simplicity!and!stability,!potentially!allowing!patients! to! test!at!home!following!
meals.! In! our! sample! there! failed! to! be! significant! correlation! of! baseline! 120!minute! post!
MMTT!UCPCR!with! 90!minute!MMTT! C8peptide! or! C8peptide!MMTT! AUC,!which! remained!
non8significant!despite!matching!the!statistical!non8parametric!analysis!used!in!the!Besser!et!
al.! paper.! Of! the! 72! T1D! subjects! examined! in! this! paper! the! upper! limit! of! UCPCR! was!
approximately! 10nmol/mmol! compared! to! the! wide! range! between! 0.40! and! 83.4!
nmol/mmol! (Figure! 24).! Significant! correlations! between! 120! minute! UCPCR! and! 90!










A.*From*Besser*et*al.*201173* correlation*of* stimulated*C:peptide*and*UCPCR* in*subjects*with*
established* Type* 1* diabetes.* Dotted* lines* show* equivalence* of* >0.2nmol/L* C:peptide* and*
>0.53nmol/mmol*UCPCR*levels*calculated*through*linear*regression*(with*94%*sensitivity*and*
100%*specificity).*B.*Correlation*in*newly*diagnosed*MonoPepT1De*cohort.*






























I! compared! MonoPepT1De! data! with! large! scale! published! data! on! T1D! characteristics! at!




age! and! screening! autoantibodies.! The!MonoPepT1De! data! shows! slightly! higher! mean! C8
peptide!AUC!and!peak!C8peptide!than!data!from!Greenbaum!et!al.225!and!Bollyky!et!al230,!both!
of!which!datasets!include!paediatric!patients.!!When!children!are!excluded!in!the!breakdown!
of! the!Bollyky!et!al.!data,! the! figures! for!mean!C8peptide!AUC! (MonoPepT1De!0.80! (±0.64),!




















































































The! inclusion! criteria! of! peak! stimulated! C8peptide! ≥0.2pmol/L! was! failed! by! 2.9%! (1/35!
patients)!of!the!MonoPepT1De!subjects!compared!to!2.0%!(18/883!subjects)!in!the!Bollyky!et!
al.!group,!which!included!children.!Recent!data!from!Lachin!et!al58!revealed!an!almost!linear!
relationship! between! decline! in! stimulated! C8peptide! to! undetectable! levels! and! outcomes!
such!as!retinopathy!and!hypoglycaemia!risk.!This!is!in!keeping!with!earlier!data!showing!peak!
stimulated! C8peptide! levels! of! >0.2! pmol/mL! were! still! protective! against! complications! of!
retinopathy! and! nephropathy57.! Whilst! only! a! minority! of! our! screened! population! was!
excluded,! such! data! suggest! that! potential! for! immunotherapy! intervention! could! be!
widened.! This! would! be! of! greatest! benefit! in! paediatric! groups,! where! TrialNet!
demonstrated!that!9%!of!patients!less!than!8!years!of!age!fail!the!>0.2!pmol/mL!cut!off230.!In!
these!cases! lowering! the!C8peptide!cut8off!would!not!only!open! immunotherapy!options! to!
those!with! greatest! need,! i.e.! with! those!more! aggressive! disease! and! greater! prospective!
disease! burden,! but! also! target! the! population! with! the! fastest! rising! incidence10.!!
Furthermore!the!use!of!immunotherapy!could!also!be!expanded!later!into!the!disease!course.!





0403)),! compared! to!moderate! or! low! risk,! and! this! difference! is! sustained! for! 12!months!
after! diagnosis231.! Another! study! found! that! DR3! but! not! DR4! alleles! were! significant!






Just! over! a! quarter! of! TrialNet! subjects! in! interventional! trials! are! overweight! or! obese230,!
which!compares!well!with!MonoPepT1De!data! (25.9%).!Our!class! II!obese!patients! retained!
higher! levels! of! C8peptide,!which!may!be!due! to! earlier! disease!presentation! as! a! result! of!
insulin!resistance!increasing!insulin!requirements.!These!patients!showed!clear!autoimmunity!
with! positive! antibody! titres,! a! high! proportion! of! family! history! of! T1D! and! presence! of!
ketosis!at!diagnosis,!which!would! suggest! insulin!deficiency.!Obesity! is!not! fully! concordant!
with!higher!C8peptide!levels.!Three!out!of!4!obese!subjects!had!C8peptide!AUC!figures!in!the!
top!quartile!however!one!was!in!the!lowest!quartile.!!
The!MonoPepT1De! trial!baseline!data! results! show!heterogeneity! in! terms!of! stimulated!C8
peptide,! BMI! and! autoantibody! profiles.! This! is! despite! narrowing! of! the! targeted! newly!
diagnosed!population!to!a!stimulated!C8peptide!threshold,!antibody!positivity!and!presence!
of! the!HLA* DRB1*0401! allele.! Comparisons! to! other! trials! that! do! not! limit! genotype! and!
include! paediatric! groups! widen! this! heterogeneity! further.! With! many! clinical!
immunotherapy! trials! yielding! disappointing! results! there! is! a! need! to! focus! on! this!
heterogeneity,!particularly!when!considering!future!intervention!trials.!Previous!examples!of!
distinct! subgroups! in!disease!progression!or! response! to! treatment!have!been! reported.! In!
disease! prevention,! post:hoc! analysis! of! the! Diabetes! Prevention! Trial! of! Type! 1! diabetes!
(DPT81)!showed!that!the!presence!of!IAA!>80!nU/mL!in!high8risk!subjects!reduced!the!risk!of!
developing! T1D! following! oral! insulin! treatment! (hazard! ratio! 0.566,! 95%! CI! 0.361–0.888;!
P=0.015)!and!delayed!disease!onset!by!4.5!years78.!This!benefit!substantially!increased!when!
IAA! levels! of! >300nU/mL! were! considered,! delaying! disease! for! nearly! 10! years232.! IAA!
positivity! was! also! linked! to! outcome! in! treatment! with! Otelixizumab,! with! multivariate!
analysis! showing! the! presence! of! IAA! (P=0.022)! or! the! interaction! of! IAA! and! C8peptide!
(P=0.013)!independent!predictors!of!outcome!to!treatment80.!Mamchak!et!al233!combined!in:
silico! disease! modelling! and! preclinical! clinical! models! to! look! at! predictors! of! outcome!












effector! and! CD8+! effector! memory! T8cells! were! also! seen! in! responders! versus! non8
responders.!!!
The! HLA! composition! of! patient! groups! has! not! been! found! to! influence! intervention!
outcomes,!with!the!exception!of!Diapep277!therapy234!where!adults!with!low!and!moderate!
risk!HLA!groups!appeared!to!benefit!most.!This!finding!will!require!validation.!!!
This! chapter! has! outlined! the! strategies! and! potential! pitfalls! in! recruiting! to! an! immune!
intervention!trial!in!T1D!and!the!need!to!exploit!avenues!of!information!dissemination!whilst!
retaining! the! integrity! of! responses! within! a! narrow! timeframe.! Baseline! data! have!
highlighted!disease!heterogeneity!despite!restriction!to!a!newly!diagnosed!adult!cohort!with!
the!presence!of!an!HLA*DRB1*0401!allele.!Such!heterogeneity!appears!to!be!a!common!factor!
in! T1D! studies,! with! suggestions! that! endotypes! of! disease! are! defined! by! discrete!
pathophysiological!mechanisms235.!Such!endotypes!have!implications!for!potential!treatment!
efficacy.!Careful!stratification!of!subjects!needs!to!be!considered!in!the!design!of!intervention!









visit! in!February!2015.!Unblinding!of! treatment!allocation!began! in!April!2015.!This!chapter!
presents!the!clinical!and!immunological!outcomes!from!the!trial.!!
4.2 Results'
Of! the!24!patients! randomised,!3!did!not! complete!a!minimum!of!11!out!of!12! treatments!
(one! from! the! low! frequency! and! 2! from! the! high! frequency! group)! and! additional!
replacement! subjects!were! recruited.!All! treated! subjects!were! included! in! the!analysis.! ! In!
total! there!were!10! subjects!allocated! to! the! low! frequency! treatment!group,!9! subjects! in!
the!high!frequency!treatment!group!and!8!subjects!in!the!placebo!group.!Two!subjects!were!
lost!to!follow8up!and!two!declined!follow8up!visits.!Baseline!characteristics!of!the!treatment!





Table' 23:' Baseline' characteristics' of' subjects' within' low' frequency,' high' frequency' and'
placebo'groups.'
! C198A3!Peptide!Immunotherapy! !
! Low!frequency! High!frequency! Placebo!
Number!of!subjects! 10! 9! 8!
Mean!age!(years±SD)! 26.6±5.5! 30.0±5.7! 28.9±8.2!
Gender! 4!Female:!6!Male! 3!Female:!6!Male! 2!Female:!6!Male!





1! 50.0%! 11.1%! 12.5%!
2! 30.0%! 11.1%! 25.0%!















The! primary! endpoint! was! the! safety! assessment! of! PI! C198A3! treatment,! which! was! well!
tolerated! with! no! hypersensitivity! reactions.! No! serious! adverse! events! were! considered!
linked! to! treatment.! Local! erythematous! reactions! previously! described! with! C198A3!
peptide117!were!present!in!both!treatment!and!placebo!groups.!These!skin!reactions!were!not!
associated!with! local!wheal!or!swelling,!and!did!not!change! in!size!or!quality!with!repeated!
peptide! administration.! Skin! reactions!were! present! in! 8/9! subjects! in! the! high! frequency,!
10/10! subjects! in! the! low! frequency! and! 4/8! subjects! in! the! placebo! group.! Five! serious!

































analysis! adjusted! for!baseline!value!of!AUC,!which! showed!no! significant! treatment8related!




evident! in! individual! data! plots:! compared! with! baseline,! C8peptide! levels! in! subjects!
receiving! placebo! showed! a! decline! at! every! timepoint! in! every! subject! (apart! from! one!
subject,!at!6,!9!and!12!months)!and!mean!values!declined!significantly! in!paired!analyses!to!
baseline.!This!contrasted!with! findings! in! the! treatment!groups,! in!which! the!mean!percent!



















































1017 0.51 0.64 24.70! 0.26 -49.82 0.26 -49.82 0.12 -77.10 
1019 2.57 1.89 -26.31 1.16 -54.74 3.38 31.32! 2.16 -15.87 
2010 1.28 0.74 -42.19 0.78 -38.87 0.74 -42.19 0.74 -41.97 
2011 1.72 1.14 -34.02  NA  NA 0.76 -56.11 2017 0.50  NA 0.29 -42.64 0.30 -41.15 0.28 -43.58 2021 0.58 0.50 -13.25 0.87 49.30! 0.31 -46.71 0.43 -26.62 
2025 0.58 0.51 -12.20 0.28 -52.47 0.48 -18.17 0.38 -34.19 
3015 0.56 0.88 57.87! 0.36 -36.30 0.48 -14.89 0.47 -16.01 










1024 0.32 0.20 -36.11 0.61 90.50! 0.25 -19.99 0.24 925.29!
2001 0.62 0.28 -53.90 0.56 99.32! 0.51 -17.27 0.37 940.02!
2006 1.27 1.12 -12.46 0.73 942.74!  NA  NA!
2016 0.31 0.05 -83.89 0.05 983.89! 0.05 -83.89  NA!
2018 0.53 0.56 5.38! 0.37 929.95! 0.41 -22.03 0.39 926.11!
2020 0.72 0.19 -73.52 0.26 963.28!  NA  NA!
2027 0.49 0.95 94.03! 0.66 36.37! 0.91 87.68! 0.62 26.30!
2031 2.80 5.12 83.06! 2.74 91.97! 3.21 14.75! 1.94 930.47!
4007 0.76  NA 0.88 15.26! 1.35 76.23! 0.77 0.57!






1008 0.30 0.19 -37.20 0.11 -63.10 0.09 -70.21 0.05 983.47!
1025 0.36 0.08 -77.30 0.50 39.60! 0.30 -15.77 0.36 90.52!
2019 0.44 0.20 -53.44 0.19 -56.24 0.30 -30.34 0.50 15.78!
3002 0.99 0.23 -76.29 0.10 -89.93 0.21 -78.59 0.15 985.25!
3005 0.68 0.36 -46.57 0.26 -61.20 0.37 -46.30 0.19 971.95!
3012 0.85 0.47 -44.94 0.75 -11.68 0.89 4.95! 0.69 918.92!
4001 0.62 0.24 -61.39 0.18 -70.87 0.08 -87.30 0.18 971.52!






AUC# C=peptide# from# baseline# is# shown# in# groups# receiving# placebo# (open# squares),# low#




3,# 6,# 9# and# 12#months# in# groups# receiving# placebo# (open# squares),# low# (triangle)# and# high#
(inverted#triangle)#frequency#C19=A3#peptide#over#12#months.#There#is#a#significant#reduction#
in# the# stimulated# C=peptide# level# in# the# placebo# group# at# each# time# point.# No# significant#















(p=0.009)! compared! with! placebo,! with! an! overall! difference! between! the! treatment! and!
placebo! groups! across! all! time! points! in! multilevel! model! repeated! measures! analysis! (p=!
0.01)!(Figure!26A).!
Glycaemic! control!was! intensively!managed! in! the! study,!with! a! target! HbA1c! of! less! than!





number!of! limitations.!As! the! goal! of! clinical!management! is! glycaemic! control,! both! these!
measures!are!influenced!by!exogenous!insulin!and!the!many!factors!that!guide!insulin!dose.!
Mortensen!et!al.236! introduced!the! insulin!adjusted!A1c! (IDAA1C)!as!a!marker!of! residual!βV
cell!function.!IDAA1C!is!calculated!as!A1C!(percent)!+![4!x!insulin!dose!(units!per!kilogram!per!
24!h)].!An! IDAA1C!≤9%!was! found! to! correspond! to!a!predicted! stimulated!CVpeptide!>300!
pmol/l! and! was! used! to! define! partial! remission236.! The! placebo! group! had! consistent!






maintenance! (change! of! <50%! of! the! interassay! coefficient! of! variation! of! the! CVpeptide!
assay)!in!CVpeptide!response!to!a!MMTT.!There!were!10!such!“CVpeptide!responder”!subjects!











A.#Mean#change# in#average# insulin#dose# from#baseline# is# shown# in#groups# receiving#placebo#
(open#squares),# low#(triangle)#and#high#(inverted#triangle)#frequency#C19=A3#peptide#over#12#
months.# There# was# a# progressive# increase# in# insulin# requirement# in# the# placebo# arm.# In#
contrast# there#was# a# reduction# or# stabilization# in# the# low# and# high# frequency# groups,#with#
significant#differences#in#change#compared#with#placebo#in#the#high#frequency#group#at#month#
6#(*;#p=0.03),#month#9#(*;#p=0.04)#and#month#12#(*p=0.01)#and#low#frequency#group#at#month#




deviations.# C.# Insulin# dose# adjusted# HbA1c# (IDAA1c)# values# following# treatment# were#
significantly# lower# in# the# high# frequency# arm# at# baseline,# 3,# 6,# 9# and# 12#months# (*p=0.02,#
p=0.001,# p=0.003,# p=0.01# and# p=0.002,# respectively)# and# significantly# lower# in# the# low#
frequency#arm#at#6#and#12#months#(†p=0.05#and#p=0.01,#respectively)#compared#with#placebo.#
4.2.5 Immune'assays'
Over! the! duration! of! the! treatment! period,! cumulative! CD4! TVcell! ILV10! responses! to!
proinsulin!stimulation!were!significantly!higher!in!the!blood!of!the!high!frequency!compared!
with! placebo! (p=0.015)! and! low! frequency! groups! (p=0.003).! There! were! no! significant!




activated! CD8! TVcells! specific! for! βVcell! target! peptides! between! these! groups! (data! not!
shown).!
Using!the!responder!definition!as!those!with!an!increase!(a!positive!change!from!baseline)!or!
maintenance! (change! of! <50%! of! the! interassay! coefficient! of! variation! of! the! CVpeptide!
assay)! in! CVpeptide! response! to! a! MMTT! to! compare! responders/nonVresponders,! at! 2!
months,! ILV10! responses! against! PI! were! significantly! higher! in! peptideVtreated! CVpeptide!
responders!(p=0.007)!and!higher!levels!of!ILV10!responses!were!maintained!in!the!responder!
group.! PeptideVtreated! CVpeptide! responders! (but! not! nonVresponders)! showed! a! trend! for!






represent# peptide# treated# C=peptide# responders# and# filled# circles# represent# non=responders.#
Across# the# treatment# period# IL=10# responses# to# proinsulin# stimulation# rose# and# were#
significantly# higher# in# the# C=peptide# responder# group# compared# with# non=responders#
(p=0.007).#Peptide=treated#C=peptide#responders#(but#not#non=responders)#showed#a#trend#for#




and# were# analyzed# with# linear# models# having# visit# and# treatment# as# main# factors# and# a#














intracellularly! stained!using! antiVKi67VFITC! (B56;! BD),! antiVFOXP3VAlexa! Fluor! 647! (259D/C7;!
BD!Biosciences)!and!antiVHeliosVPacific!blue! (22F6;!BioLegend,! San!Diego).! !Data!acquisition!
was!performed!using!a!BD!Biosciences!LSRFortessa!cell!analyzer.!!
CD57+! (antigenVexperienced)! effector! memory! βVcell! peptideVspecific! CD8! TVcells! were!






increase! in! the! peptideVtreated! CVpeptide! responders! compared! to! nonVresponders! (Figure!
28A).!Levels!returned!to!baseline!at!12!months!and!were!unchanged!throughout!the!study!in!
CVpeptide! nonVresponders.! The! greatest! foldVchange! in! FoxP3! expression! was! seen! in!
CD45RAV! (memory)!Treg!subVpopulations! that! lacked!Helios!expression,!especially! those!coV





Figure' 28:' Change' in' expression' of' FoxP3' between' peptide/treated' C/peptide' responders'
and'non/responders'at'6'months'compared'to'baseline.'''
(A)# Change# within# all# Treg# subsets.# (B)# Change# within# memory# (CD45RA=)# adaptive# Tregs#








The! proportion! of! CD8! TVcells! specific! for! βVcells! that! expressed! the! diseaseVassociated!





placebo! at! 6! months.! As! observed! in! our! previous! studies! in! new! onset! type! 1! diabetes!
patients,!TVcell!responses!to!C19VA3!at!baseline!were!present!in!a!small!minority!of!patients;!









shown! evidence! of! benefit! in! preclinical! models110,113,238,239,! with! PIT! regimens! for! allergy!
already!being!well!established!in!clinics.!The!MonoPepT1De!trial!aimed!to!establish!the!safety!
and! immunological! effects! of! a! naturally! processed! and! HLAVDR4! presented! proinsulin!
peptide! C19VA3! in! new! onset! T1D.! Repeated! dosing! of! 10μg! of! peptide! at! 2! or! 4! weekly!
intervals! for! 6! months! was! well! tolerated! and! not! associated! with! hypersensitivity! or!
acceleration!of!βVcell!loss.!!
CVpeptide!decline!occurred! early! and!was!maintained! in! the!placebo! group,!whereas! those!
receiving! peptide! treatment! had! comparably! less! early! CVpeptide! loss,! with! loss! being!





baseline! HbA1c! and! insulin! dose! in! the! high! frequency! treatment! group! and! small! subject!
numbers,! HbA1c,! mean! insulin! dose! and! IDAA1c! data! appear! to! support! the! improved!
metabolic!control!and!residual!βVcell!function!in!treated!groups!over!placebo.!In!a!small!study!
such! as! this! there! are! difficulties! in! balancing! out! baseline! inequalities,! which! may! exist!
despite! the! randomization! process.! Those! receiving! peptide! treatment! had! stable! mean!
insulin!doses!without!compromise!in!glycaemic!control!as!HbA1c!fell!or!stabilised,!compared!
to! rising! HbA1c! in! placebo! despite! increasing! insulin! administered.! Whilst! high! frequency!
dosing! was! safe! it! did! not! confer! additional! benefits! over! low! frequency! administration,!
despite!showing!higher!cumulative!ILV10!responses.!The!increment!in!ILV10!response!was!not!
sufficient! to! infer! any! additional! effect! on! metabolic! parameters,! and! to! explore! the!
mechanistic!responses!further!dose!response!studies!would!be!beneficial!with!a!wider!span!
of!doses!than!used!in!this!study.!!
The! definition! adopted! in! this! study! was! one! previously! used! in! an! immunotherapy!
intervention!trial!by!Herold!et!al.97!equating!to!a!threshold!of!92.5%!or!more!of!baseline.!As!
such!this!responder!status!may!include!those!with!slowed!βVcell!decline!as!well!as!those!with!
preservation,! which! may! be! an! analysis! more! suited! to! a! small! phase! I! study.! Difficulties!
defining!clinical!response!to!treatment!can!be!due!to!lack!of!an!accepted!consensus!definition!
of!responder,! intraVsubject!variability! in!CVpeptide!AUC!and! lack!of!studies! linking!CVpeptide!
with! definitive! clinical! endpoints.! Beam! et! al.240! reviewed! these! issues!when! considering! a!
definition! of! responders! within! insulin! preservation! studies,! where! they! conclude! that! a!
prespecified!definition!of!a!clinical!responder!should!be!maintenance!or!increase!of!CVpeptide!
from! baseline,! i.e.! a! threshold! of! 100%! or! more! of! baseline! CVpeptide! AUC! values.! The!
responder! status! should! be! considered! a! supportive! analysis,! which! in! our! case! drove! a!
number! of! interesting! findings! of! immunological! differences! between! responder! and! nonV
responders,!which!were! not! present! between! treatment! groups.! Importantly! tightening! up!
the! threshold! to! 100%! would! not! have! changed! the! divide! between! responders! and! nonV
responders! in! this! study,!which!reinforces!confidence! in!allocation!of! responder!status.!The!
limitations! of! responder! analyses! have! been! previously! reported! by! Greenbaum! et! al.225!






considered! a! key! mechanism! of! tolerance! induction! in! ASI! and! PIT.! ELISPOT! data! showed!





upregulation!were!also!Helios!negative,! suggesting! that! these!were!peripherally! generated,!
adaptive! Tregs.! It! is! proposed! that! autoantigenVspecific! CD4! TVcells!with! immunoregulatory!
properties!are!induced!and!suppress!bystander!inflammatory!responses!to!the!same!epitope,!
autoantigen!or! related!autoantigens!being!presented! in! cis!by! the! same!antigenVpresenting!
cell!(APCs)121.!There!is!also!evidence!that!under!these!conditions!APCs!are!licensed!to!induce!
new! cohorts! of! regulatory! TVcells! in! a! process! termed! “infectious! tolerance”242.! Such!
infectious!tolerance!may!be!a!mechanism!of!action!by!which!proinsulin!C19VA3!could!induce!
ILV10+! proinsulinVspecific! CD4! TVcells! and/or! adaptive! Tregs,! leading! to! amelioration! of!
disease.! Lower! levels! of! CD57! expressing! CD8! TVcells! were! found! in! peptideVtreated!
responders,! with! CD57! expression! an! indicator! of! recent! antigen! exposure237.! This! finding!
may! indicate! that! subjects! who! show! restricted! activation! of! autoreactive! cytotoxic! T!
lymphocytes!may!be!more!amenable!to!immune!effects!induced!by!PIT.!!!
In! summary! this! study! has! established! the! safety! of! proinsulin! C19VA3! in! adults! newly!















groups! refining! capture! of! an! antigenVspecific! response! in! live! CD4+! TVcells! after! ex=vivo!
stimulation!through!detection!of!induced!surface!CD154!expression205,206,243,244.!The!methods!
have! been! shown! to! be! robust! and! sensitive! in! detecting! potentially! rare! activated! CD4+!
cells244! and,! with! CD154! upregulation! via! bystander! activation! being! low! and! having! low!
constitutive! levels,!this!marker! is!more!specific!than!other!activation!markers!such!as!CD25,!
CD134,!CD69,!CD137!or!HLAVDR243.!The!assay!was!validated!further!within!our!own!laboratory!
by! comparing! antigenVspecific! populations! enriched! via! this!method! versus! antigen! specific!
responses! detected! by! ELISPOT178.! ! Using! sensitive! ELISPOT! techniques! in! an! index! donor!
~0.012%! PBMCs! were! detected! to! secrete! IFNγ! in! response! to! shortVterm! (16! hour)!
stimulation!with!HA306V318! peptide.! In! comparison,! using!HA306V318! in! the! antigen! stimulation!
assay! and! sorting!CD154+/CD69+!CD4+! cells,! 24.5%!of! 49! clones!obtained!and! tested!were!
specific! for!HA306V318!when!using! IFNVγ!production!as! the! readVout,!which! indicates!≥20,000V





was! standardised! throughout! the! course! of! the! clinical! trial! a! number! of! measures! were!
taken,!including:!




















5.3 Comparison' of' anti/CD40' antibody' clones' in' antigen' stimulation'
assay.''
Addition!of!antiVCD40!blocking!antibody!prevents!internalisation!of!CD154!allowing!optimised!
collection! of! live! antigenVresponsive! CD4+! TVcells206.! The! assay! was! previously! performed!
successfully!within!our! laboratory!using!an!antiVCD40! (G28.5! clone)! antibody!donated! from!
M.!Frentsch!(Berlin).!In!order!to!find!a!suitable!replacement!for!the!duration!of!the!trial,!this!
antibody!was!compared!to!two!commercially!available!antibodies;!another!G28.5!clone!and!a!
5C3! clone! (both! Biolegend,! London,! UK).! The! stimulation! assay! (as! outlined! in! section! 2.9)!
was!carried!out!using!Pediacel®!as!an!antigen!stimulus!with!cells!from!a!healthy!donor!with!













TCR! and! gene! expression! experiments! rely! on! the! isolation! of! CD4+! TVcells! exhibiting! the!
activation!markers! of! CD69! and! CD154! in! response! to! antigen! stimulation.! To! identify! the!
optimal! flow! cytometry! gating! strategy,! experiments!were! performed! in! collaboration!with!
lab!members,!Dr!H.!Shariff!and!Dr!V.!Gibson.!The!aim!was!to!assess!antigen!specific!clones!in!




as! outlined! in! section! 2.9,! and! antigenVinduced! proliferation! and! IFNVγ! production! were!



















identified! from! the! CD69low! CD154+! (P8)! gate! and! 6! positive! Pediacel®! clones! from!
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At! each! flow! cytometry! experiment,! a! positive! control!was! added! in! the! form!of! a! thawed!
cryopreserved! PBMC! sample! from! a! control! donor! stimulated! with! SEB.! The! aim! of! this!
control!was!to!provide!an!assessment!of!the!reproducibility!of! the!antigen!simulation!assay!
over! the!course!of! the! trial.!The!PBMCs!were!cryopreserved! from!3!venesection!collections!
from! a! single! haemochromatosis! donor! over! the! course! of! 3! months.! The! SEB! stimulated!
control!samples!were! incorporated! into!the!assay!during!a!period!of!over!2!years,!between!
July! 2012! and! August! 2014.! The! percentage! of! CD69+/CD154+! cells! (from! the! parent! CD4+!
population)!from!all!SEB!stimulated!cryopreserved!samples!are!plotted!in!Figure!32.!The!data!
are!also!divided! into! two! further!groups!depending!on!which!of! two! flow!cytometers!were!
used!to!analyse!the!sample,!internal!departmental!equipment!versus!external.!Coefficients!of!
variation!(CV)!values!of!these!data!were!high,!with!CV!being!58.8%!in!total!data!and!22.1%!in!
the!external! group! versus!61.8%! in! the! internal! group.! In! view!of!high!CV! values,! potential!
outlying! results!were! examined.! Technical! errors! (marked! in! Figure! 32)!were! suspected! for!
two!very!high!data!points,!identified!possibly!due!to:!!
1. Excess! SEB! stimulation! V! supported! by! disproportionately! high! CD69+/CD154+! cell!
frequency! in! both! SEB! control! group! and! the! SEB! patient! samples! analysed! on! the!
same!day.!
2. Excess! coVstimulation!with!antiVCD28!antibody! V! supported!by!over!10Vfold! increase!
from!baseline!in!mean!cell!numbers!across!all!stimuli.!!
Cryopreserved! cells!were! used! to! enable! repeated! sampling! from!a! single! control! over! the!
course!of!the!trial,!as!fresh!control!samples!would!not!be!feasible!in!this!setting.!To!analyse!
the! longVterm!effect! of! cryopreservation! on! these! samples! the! frequency! of! CD69+/CD154+!
post!SEB!stimulated!was!plotted!chronologically!(Figure!33).!Figure!33!shows!the!variation!in!




been! standardised! throughout! the! trial! as! such! methods! can! influence! antigenVspecific!
responses,! through! assays! such! as! ELISPOT245.! Supplementary! experiments! performed! by! a!





month! cryopreservation! period,! on! the! antigenVspecific! response! of! PBMCs! to! GAD! and! PI!
peptides,! control!protein,!Pediacel®! and!PBS! in! terms!of! IFNVγ!and! ILV10!production! (Figure!




the! two!assays!versus! the!average.!Also!plotted!are! the!mean!biases!and! the!95%! limits!of!
agreement,!defined!as!mean!bias!±2SD.!The!plots!shown!in!Figure!36,!illustrate!that!there!are!
significant! discrepancies! between! the! fresh! and! thawed! assays! with! no! clear! relationship!
between! results.!Wide! bands! of! 95%! limits! of! agreement!would! be! of! clinical! significance;!
therefore!interpretation!of!results!from!thawed!cells!would!be!unreliable.!!!!
Figure' 32:' Percentage' of' CD69+/CD154+' cells' from' parent' CD4' population' within' SEB'
stimulated'control'samples.''
Total# data# are# shown# in# addition# to# data# divided# by# internal# or# external# flow# cytometry#
facility.#Lines#indicate#median#and#interquartile#range.#P#value#calculated#using#unpaired#t=test#
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Figure' 33:' Variation' in' frequency' of' CD69+/CD154+' cells' post' SEB' stimulation' of'
cryopreserved'cells'over'time.''


































Figure' 34:' ELISPOT' images' of' IL/10' and' IFN/γ' antigen' specific' responses' using' fresh' and'
cryopreserved'PBMCs'from'a'single'individual.'Courtesy'of'Dr.'Iria'Gomez/Tourino.'
Images#show#triplicate#wells#with#number#of#responsive#cells#in#each#well#labelled#in#the#right=























































































































Figure' 36:' Bland/Altman' analysis' of' ELISPOT' assays' on' fresh' and' thawed' cryopreserved'
cells.'Data'courtesy'of'Dr.'Iria'Gomez/Tourino.'
The# solid# lines# mark# mean# bias# and# dashed# lines# mark# the# 95%# limits# of# agreement# for#
stimulation#index.#



























































































immune! response! as! it! identifies! cells! which! may! provide! BVcell! help! or! activate! APC!





When!examining!cells! for!CD69!and!CD154!positivity,! there! is!a!clearer!distinction!between!
CD154! positive! and! negative! cells! than! CD69! positive! and! negative! cells.! This! necessitated!
further! functional! identification! of! CD69+! cells! in! order! to! gate! these! cells! effectively.! The!
clones! identified! within! the! P8! gate! showed! less! antigenVspecific! proliferation! and! IFNVγ!
production!than!those!in!the!P7!gate.!In!view!of!these!findings!the!cells!were!collected!from!
the! P7! gate!without! expanding! collection! to! the! P8! gate,! to! isolate! cells!with! the! greatest!
antigenVspecific! response.! The! functionality! in! terms! of! IFNVγ! production! was! assessed! via!
ELISA.! Chattopadhyay! et! al205! were! able! to! demonstrate! that! CD154! cells! showed!multiple!
diverse!TVcell!function!through!intracellular!staining!and!polychromatic!flow!cytometry.!
Repeated! stimulation! of! cryopreserved! control! samples! using! the! super! antigen! SEB! was!
performed!to!examine!reproducibility!of!the!assay!longitudinally.!The!design!and!the!duration!
of! the! trial! required! multiple! operators! to! process! assays,! and! during! each! experiment!
multiple!operators!shared!variable!points!in!the!assay,!therefore!defining!individual!operator!
effects! is!not!possible.! IntraVassay!variability!was!not!assessed,!as!only!one!SEB!control!was!
present! per! experiment.! InterVassay! variability! was! measured! using! the! percentage! of!











20.7%,! 39.9%,! 52.3%! and! 68.3%.! Cryopreservation! being! used! in! control! cells! alone!would!
suggest!that!the!high!CV!levels!do!not!reflect!on!the!reproducibility!of!the!stimulation!assay,!
but!would!have!implications!on!use!of!patient!cryopreserved!samples.!!
Importantly! these! changes! in! response! were! not! predictable! with! rise! or! falls! varying!
between!individuals.!PBMCs!which!have!been!cryopreserved!for!a!period!of!one!month,!have!
been! shown! to! have! comparable! results! to! fresh! PBMCs!when!used! in! peptide! stimulation!
cytokine! flow! cytometry! assays246.! Supporting! work! by! Dr! GomezVTourino! shows!
unpredictable! discrepancies! between! antigenVspecific! responses! pre! and! post! a!
cryopreservation!period!of!3.3Vmonths.!The!samples!used!within!the!trial!were!cryopreserved!
for!approximately!2!years!with!deterioration!in!reproducibility!being!present!from!6!months.!
There! is! little! published! data! on! the! effects! of! longVterm! cryopreservation! on! PBMC!
responses,! however! Owen! et! al.247! examined! the! effects! of! cryopreservation! on! a! control!
group!(n=8)!against!HIV!positive!samples,!which!were!banked!for!over!300!days.!They!showed!
that!PBMC!samples!were!able!to!retain!CD4+!and!CD8+!TVcell! IFNVγ!responses!to!CMV!pp65!
after! longVterm! cryopreservation! regardless! of! HIV! status.! Although! there!was! a! decline! in!
CD4+! responses! in! controls,! the! authors! felt! that! the! rank! order! of! the! responses! was!
retained! and! consistent! enough! to! have! comparable! results! on! a! population! basis.!
Nonetheless!HIVV!samples!were!only!tested!for!IFNVγ!response!against!CMV!pp65!leaving!the!
possibility! of! individual! responses! to! other! antigens! being! affected! as! illustrated! by! the!
ELISPOT!example!(Figure!34)!where!antigenVspecific!responses!can!vary!depending!on!antigen!
stimulus!and!cytokine!response.!
The! use! of! a! stimulation! assay! within! the! MonoPepT1De! trial! has! required! generalised!
standardisation!of!reagents!and!lab!procedures!as!well!as!assay!specific!considerations.!I!have!
described!a!number!of!stages!of!development,!including!antibody!comparison!and!identifying!
functionality! of! cells! phenotyped! through! flow! cytometry.! The! choice! of! a! stable! control!
















clonotype! frequency! (R2=0.98,! p=0.001)!when! identifying! a! known! clonotype! spiked! into! a!





2. To! investigate! the! size! and! structural! diversity! of! an! antigenVspecific! βVchain! TCR!
response! to! PI! C19VA3! in! patients! newlyVdiagnosed!with! T1D! in! response! to! PIT! or!
placebo.!!
3. To! identify!βVchain! clonotypes! (defined!as!distinct! TCR! sequences)!which!are!public!










tags! were! engineered! by! Roche! (Sussex,! UK)! to! complement! their! Roche®! 454!




BLAST249! search! to! identify! target! sequences.! The! secondary! structures! of! MIDVlabelled!
primers! were! interrogated! in# silico# for! hairpin! formation,! dimerization! to! self! or! to! the!
forward! primer,! 5’RACE! F! using! the! PrimersList!webtool250.! Subsequently! in# vitro! testing! of!
relative! efficiencies! of!MID! labelled! primers! was! performed! through! RTVPCR! (2.11.6).! Each!
PCR!run!contained!triplicates!of!12!MID!samples!and!was!repeated!in!triplicate.!Due!to!lack!of!
first!round!PCR!product!to!use!for!MID!validation,!RTVPCR!was!performed!directly!using!cDNA!




The!NCBI!BLAST! search! confirmed!high! specificity! for! the!human!TVcell! receptor!beta! chain!
remained!despite!MID!labelling,!with!expect!values!of!<0.001.!
































































































being! a! potential! G/CVquadruplex.! Reactions! using! MID! 8! failed! to! show! exponential!






in! 2.11.! The! number! of! samples! that! could! be! processed! were! limited! by! time,! cost! and!
number!of! valid!MID! tags,! therefore! the! longitudinal! samples!of! PI! C19VA3! stimulated! cells!
were! prioritised! for! sequencing.! Unblinding! of! treatment! groups! was! not! performed! until!




potentially! can! incorporate! bias! from! sample! size.! Data! analysis! was! performed! with!
bioinformatics!support!(Dr.!Anna!Lorenc,!KCL).!!
Diversity!measures!in!TCR!populations!can!determine!whether!there!are!detectable!shifts!in!
clonotypes.! For! the! purposes! of! this! thesis,! diversity! refers! to! structural! diversity! resulting!
from!the!recombination!of!the!VDJ!regions,!in!contrast!to!functional!diversity!which!refers!to!
the! range!of!different!effector! functions! from!activated!TVcells!which! share! specificity! for!a!
single!epitope.!When!assessing!diversity!of!a!TCR!population,!diversity!measures!can!consider!
the!number!of!different!clonotypes!present!as!well!as!distribution!of!clone!size! (number!of!





were!used! in! this!TCR!data,! the! true!diversity,! the!Gini! index!and! the!Chao1! index.!Using!a!
combination! of! diversity! measures! allows! for! assessment! of! differing! aspects! of! diversity.!
True! diversity! is! defined! as! the! number! of! equally! abundant! types! needed! for! the! average!
proportional!abundance!of!the!types!to!equal!that!observed!in!the!dataset!of!interest!where!
all!types!may!not!be!equally!abundant.!The!Gini!index!is!a!measure!of!inequality!derived!from!
economic! data! analysis! of! distribution!of!wealth,! a! score! of! 0! equating! to! a! perfectly! even!
distribution! of! species! and! higher! scores! suggesting! greater! inequality.! The! Chao1! index!
indicates! the! richness! of! a! population.! True! diversity! is! the! reciprocal! of! the! weighted!
generalized!mean!of!the!proportional!abundances!of!the!types!in!the!dataset.!












During! sequencing! the! presence! of! low! clone! size! can! indicate! sequencing! errors! or! the!
presence!of!rare!clones,!which!may!skew!results!especially! in!larger!samples.!To!reduce!this!




diversity!across!treatment!groups,! there!were!no!significant!changes!detected! in!any!of! the!
diversity!measures!over!time.!!
6.4.2 Results'
A! number! of! samples! required! repeated! amplification! steps! to! enable! adequate! final! DNA!
concentrations.! Final! DNA! concentrations! were! variable! as! initial! RNA! concentration! could!
not! be! predicted! from! cell! number! and! small! volumes! of! eluates! at! each! stage! made!
quantification! of! nucleic! acid! difficult! without! significant! loss! of! product.! Only! at! gel!
electrophoresis!stage!would!a!visible!band!at!approximately!500bp!provide!an! indication!of!
adequate!product!and!even!beyond!this!step!a!number!of!samples! failed!quality!control!by!
fragment! analysis! prior! to! pooled! multiplex! sequencing.! With! the! added! issue! of! missed!






Samples# were# divided# into# two# datasets# that# were# sequenced# on# separate# runs.# Left# hand#
columns# indicate# patient# numbers# with# treatment# groups# of# placebo# (P),# high# frequency#
dosing#(H)#and#low#frequency#dosing#(L).#Visits#1#(baseline),#3#(1#month)#and#9#(5#months)#are#
indicated#by#V1,#V3#and#V9#respectively.#MID#allocation#is#indicated#for#each#patient#and#visit#




In! total! both! datasets! yielded! data! for! 78,107! sequences.! Normalisation! of! data! was!
considered!in!view!of!variations!in!cell!numbers!between!samples!that!could!have!influenced!
the! diversity! of! sequences! identified! and! bias! towards! greater! diversity! in! larger! samples.!
Median! cell! number! per! sample! was! 711! (range! 80V12,968).! No! correlation! was! found!









R! 95%!confidence!interval! RVsquared! P!value!
Total!number!of!sequences! V0.064! V0.365!to!0.248! 0.004! 0.690!
Total!number!of!productive!
sequences! V0.092! V0.389!to!0.2219! 0.008! 0.567!
Number!of!unique!productive!
CDR3!amino!acid!sequences! 0.202! V0.112!to!0.480! 0.041! 0.2046!
Number!of!unique!productive!
CDR3!nucleotide!sequences! 0.199! V0.115!to!0.478! 0.040! 0.211!
!







Figure' 38:' Changes' in' diversity' measures' of' amino' acid' level' clonotypes' in' treatment'
groups'over'time'
Graphs#show#true#diversity,#Gini=Simpson#index#and#Chao#1#measures#for#individual#samples#in#
treatment# groups# over# visits# 1,# 3# and# 9.# True# diversity# and# Gini# indexes# were# calculated#
excluding#unique#single#sequences.#Overlaying#bars#indicated#median#and#interquartile#range#


















































Identification! of! identical! βVchain! CDR3! regions! could! be! seen! between! multiple! samples,!
both!within!and!between!patients.!125!(102!productive)!sequences!were!shared!at!an!amino!




these! differed! by! only! 1! nucleotide! but! 9! (50.0%)! differed! by! 2,! 3! or! 4! nucleotides! and! 1!
(5.5%)!differed!by!5!nucleotides.!There!was!a! fall! in!number!of!convergent!clonotypes!with!
increasing!number!of!alternative!convergent!nucleotides! (Figure!39A).!Similarly! there!was!a!
fall! in! the!number!of! samples! sharing!a!convergent!clonotype!as! the!number!of!alternative!
nucleotides!increased!(Figure!39B);!neither!of!these!correlations!was!significant.!Out!of!the!18!
sequences! that! showed!convergent! recombination!13!were! found! in!CVpeptide! responders,!
although!this!appears!to!be!driven!largely!by!a!single!patient!(1025).!This!patient!was!in!the!





alternative# nucleotides# within# convergence.# (B)# Graph# showing# number# of# samples# with#
convergent#clonotypes#with#differing#number#of#alternative#nucleotides.#Lines# indicate#mean#
and# standard# deviation.# r# and# p# values# are# derived# from# Pearson# correlation# co=efficient#
calculations.##






























































Underlined( CDR3( nucleotide( sequences( show( alternative( nucleotide( placement( resulting( in( identical( amino( acid( sequence.( Functionality:( P( indicates(
productive(whilst(U(indicates(unproductive(sequence.(











1017_V1_PI_MID10! TGTGCCAGCAGCCAAGGGGGCACCGGGGCCAACGTCCTGACTTTC! P! 4! 0.46!
4! 3! 3!1025_V3_PI_MID13! TGCGCCAGCAGCCAAGGAGGGACTGGGGCCAACGTCCTGACTTTC! P! 2! 0.08!
2019_V9_PI_MID16! TGTGCCAGCAGCCAAGGGGGCACCGGGGCCAACGTCCTGACTTTC! P! 1! 0.06!
1025_V1_PI_MID04! TGCGCCAGCAGCCCCGAGGGGCAGCCCCGTGAAAAACTGTTTTTT! P! 96! 10.04!
1! 3! 2!
1025_V1_PI_MID04! TGCGCCAGCAGCCCCGAGGGGCAGCCCCGTGAAAAACTGTTTTTT! U! 1! 0.10!
1025_V3_PI_MID13! TGCGCCAGCAGCCCCGAGGGGCAGCCCCGTGAAAAACTGTTTTTT! P! 208! 8.28!
1025_V3_PI_MID13! TGCGCCAGCAGCCCCGAGGGGCAGCCCCGTGAAAAACTATTTTTT! P! 5! 0.20!
1025_V3_PI_MID13! TGCGCCAGCAGCCCCGAGGGGCAGCCCCGTGAAAAACTGTTTTTT! U! 4! 0.16!
5001_V1_PI_MID12! TGCGCCAGCAGCCCCGAGGGGCAGCCCCGTGAAAAACTGTTTTTT! P! 1! 0.04!
1008_V1_PI_MID05! TGTGCCAGCAGCCGGACAGGGGGCACTGAAGCTTTCTTT! P! 31! 6.64!
1! 2! 2!1008_V1_PI_MID05! TGTGCCAGCAGCCGGACAGGGGGCACTGAAGCTTTCTTT! U! 2! 0.43!
2018_V9_PI_MID21! TGTGCCAGCAGCCGCACAGGGGGCACTGAAGCTTTCTTT! P! 13! 0.92!
1008_V9_PI_MID11! TGTGCCAGCAGTTACAGCGGCCCGGGACTAGCGGGACGCACAGATACGCAGTATTTT! P! 120! 5.80!
1! 2! 2!
1008_V9_PI_MID11! TGTGCCAGCAGTTACAGCGGCCCGGGGCTAGCGGGACGCACAGATACGCAGTATTTT! P! 2! 0.10!
1008_V9_PI_MID11! TGTGCCAGCAGTTACAGCGGCCCGGGACTAGCGGGACGCACAGATACGCAGTATTTT! U! 1! 0.05!
2021_V1_PI_MID15! TGTGCCAGCAGTTACAGCGGCCCGGGACTAGCGGGACGCACAGATACGCAGTATTTT! P! 1! 0.04!




Underlined( CDR3( nucleotide( sequences( show( alternative( nucleotide( placement( resulting( in( identical( amino( acid( sequence.( Functionality:( P( indicates(
productive(whilst(U(indicates(unproductive(sequence.(
!
1017_V1_PI_MID10! TGTGCCAGCAGTTTCTTACAGGGAGGCTATGGCTACACCTTC! P! 15! 1.71!
1! 2! 2!1017_V1_PI_MID10! TGTGCCAGCAGTTTCTTACAGGGAGGCTATGGCTACACCTTC! U! 2! 0.23!
1017_V1_PI_MID10! TGTGCCAGCAGTTTCTTACAGGGAGGCTATGGCTACACGTTC! P! 1! 0.11!
1017_V3_PI_MID22! TGTGCCAGCAGTTTCTTACAGGGAGGCTATGGCTACACCTTC! P! 2! 0.45!
1017_V1_PI_MID10! TGTGCCAGCAGCTTGGCGGAGACCCAGTACTTC! U! 2! 0.23!
3! 2! 2!1017_V1_PI_MID10! TGTGCCAGCAGCTTGGCGGAGACCCAGTACTTC! P! 2! 0.23!
5001_V1_PI_MID12! TGCGCCAGCAGCTTAGCCGAGACCCAGTACTTC! P! 14! 0.59!
1017_V9_PI_MID02! TGTGCCAGCAGCTTAGGAGGGGGGGAGACCCAGTACTTC! P! 1! 0.31! 3! 2! 2!
2018_V9_PI_MID21! TGTGCCAGCAGTTTAGGGGGGGGTGAGACCCAGTACTTC! P! 9! 0.64!
1025_V1_PI_MID04! TGTGCCAGCAGCGGAACAGGGGGCACCGGGGAGCTGTTTTTT! P! 2! 0.21!
1! 2! 1!1025_V3_PI_MID13! TGTGCCAGCAGCGGTACAGGGGGCACCGGGGAGCTGTTTTTT! P! 7! 0.28!
1025_V3_PI_MID13! TGTGCCAGCAAATTGCAAGGTCCGGGAAACACCATATATTTT! P! 1! 0.04!
4! 2! 2!2017_V9_PI_MID17! TGTGCCAGCAAGTTGCAGGGCCCTGGAAACACCATATATTTT! P! 10! 0.20!
1025_V3_PI_MID13! TGTGCCAGCAGCTTACAGGGGGCCACAGATACGCAGTATTTT! P! 5! 0.20!
2! 2! 2!2021_V3_PI_MID20! TGTGCCAGCAGCTTGCAGGGGGCAACAGATACGCAGTATTTT! P! 33! 1.19!
2021_V3_PI_MID20! TGTGCCAGCAGCTTGCAGGGGGCAACAGATACGCAGTATTTT! U! 13! 0.47!
1025_V3_PI_MID13! TGTGCCAGCAGTTTAAGGGATACGCAGTATTTT! P! 5! 0.20!
5! 2! 2!2010_V9_PI_MID06! TGTGCCAGCAGTTTGAGGGACACCCAGTACTTC! P! 1! 0.07!
1025_V3_PI_MID13! TGTGCCACCAGCAGGCGACAGGCGTCAGATACGCAGTATTTT! P! 9! 0.36! 1!
2! 2!1025_V3_PI_MID13! TGTGCCACCAGCAGGCGACAGGCGTCAGATACGCAGTACTTT! P! 1! 0.04!
2021_V3_PI_MID20! TGTGCCACCAGCAGGCGACAGGCGTCAGATACGCAGTATTTT! P! 28! 1.01!







Underlined( CDR3( nucleotide( sequences( show( alternative( nucleotide( placement( resulting( in( identical( amino( acid( sequence.( Functionality:( P( indicates(
productive(whilst(U(indicates(unproductive(sequence.(
(
1025_V3_PI_MID13! TGTGCCACCAGCAGTTACCCGGGACTTGCCAAAAACATTCAGTACTTC! P! 1! 0.04! 3!
2! 2!1025_V3_PI_MID13! TGTGCCACCAGCAGTTACCCGGGCTTAGCCAAAAACATTCAGTACTTC! P! 1! 0.04!
2021_V3_PI_MID20! TGTGCCACCAGCAGTTACCCGGGACTTGCCAAAAACATTCAGTACTTC! P! 13! 0.47!
1025_V9_PI_MID07! TGTGCCAGCAGCTTAGTAGCGGGGGGTGGTGATACGCAGTATTTT! P! 1! 0.05! 2! 2! 2!
2021_V3_PI_MID20! TGTGCCAGCAGCTTAGTAGCGGGGGGGGGAGATACGCAGTATTTT! P! 2! 0.07!
2017_V9_PI_MID17! TGTGCCAGCGACAGGGGGCTGAACACTGAAGCTTTCTTT! P! 1! 0.02! 2! 2! 2!
4005_V9_PI_MID21! TGTGCCAGCGACAGGGGCCTTAACACTGAAGCTTTCTTT! P! 98! 3.57!
2019_V9_PI_MID16! TGTGCCAGCAGCTTAGGGCAGGGAGGTCAGCCCCAGCATTTT! P! 1! 0.06!
4! 2! 2!3015_V1_PI_MID14! TGTGCCAGCAGCCTTGGACAGGGCGGTCAGCCCCAGCATTTT! P! 103! 2.81!
2021_V3_PI_MID20! TGTGCCAGCAGCCAAGATCAAGCTCAGCCCCAGCATTTT! P! 4! 0.14!
1! 3! 2!2021_V3_PI_MID20! TGTGCCAGCAGCCAAGATCAAGCTCAGCCCCAGCATTTT! U! 1! 0.04!
5001_V9_PI_MID1! TGTGCCAGCAGCCAAGATCAAGCCCAGCCCCAGCATTTT! P! 5! 0.19!
2031_V1_PI_MID4! TGCGCCAGCAGCAGTATGACAGGGAACACTGAAGCTTTCTTT! P! 3! 0.09!
1! 2! 2!
4005_V1_PI_MID20! TGCGCCAGCAGCAGTATGACAGGGAACACTGAAGCTTTCTTT! P! 1715! 59.65!
4005_V1_PI_MID20! TGCGCCAGCAGCAGTATGACAGGGAACACTGAAGCTTTCTTT! U! 12! 0.42!





When! considering! only! the! TCR! sequences! shared! between! C;peptide! responders! who!
received! peptide! treatment,! 7! sequences! were! shared! (Table! 30).! Five! sequences! were!
shared! within! samples! for! a! single! patient! whilst! 2! were! shared! between! patients.! Two!
sequences! were! found! to! have! the! presence! of! one! or! more! frameshifts! and! were!
unproductive,!whilst!the!others!were!all!largely!productive.!!!
Table& 30:& Relative& number& of& shared& clonotypes& between& peptide& treated& C<peptide&
responders.&&
Table& shows& all& TCR& samples& from& C193A3& treated& patients& who& classed& as& C3peptide&
responders& during& the& 6& months& of& treatment.& Treatment& groups& are& indicated& by& H& (high&
frequency)&and& L& (low& frequency).&Presence&of& shared&amino&acid&TCR&beta& chain& sequences&












































CASRPQGPGNTIYF! 0.65! 0.02! ! ! ! ! ! ! ! !
CASSFTVGLMKN##F! ! ! ! ! ! ! ! ! 2.05! 5.87!
CASSFTVGLMKNC#F! ! ! ! ! ! ! ! ! 0.13! 0.14!
CASSFYGWANEKLFF! ! ! ! ! ! ! ! ! 0.08! 0.04!
CASSLKGTGGSGANVLTF! 0.40! 0.16! ! ! ! ! ! ! ! !
CASSQDQAQPQHF! ! 0.10! ! ! ! ! ! ! ! 0.18!
CSGTGGRRTYNEQFF! ! ! ! ! ! ! 0.04! ! 0.84! !
Treatment!groups! H! H! L! L! L! L! L! L! L! L!
Total!number!of!shared!
sequences! 2! 3! 0! 0! 0! 0! 1! 0! 4! 4!
!
CDR3!amino!acid!lengths!of!clonotype!which!were!shared!within!all!patients!ranged!from!11!
to! 22! amino! acids! with! a! mode! of! 15! amino! acids.! This! distribution! of! CDR3! amino! acid!
lengths! in!all!patients!and!peptide! treated!responders! is! shown! in!Figure!40.! !CDR3! lengths!
shared! between! all! patients! were! normally! distributed,! but! those! found! only! in! peptide!
treated!responders!were!too!small! in!number!to!analyse.!Frequencies!of!shared!and!private!
CDR3!clonotypes,!as!well!as!CDR3!clonotypes!shared!only!within!peptide!treated!responders!
are! shown! in! Figure! 41.! There! was! no! significant! difference! in! frequencies! between! these!
groups.!!!!!!


























All shared CDR3 clonotypes
Shared CDR3 clonotypes found within 
peptide treated responders
!
Figure& 41:& Graph& shows& frequencies& of& CDR3& clonotypes& grouped& as& private,& shared&
between&patients&and&shared&within&peptide&treated&responders.&




















Private CDR3 clonotype 
frequencies
Shared CDR3 clonotype 
frequencies
Shared CDR3 clonotype 





with! the! exclusion! of! stop! codons! and! frameshifts.! Shared! CDR3! sequences! were! then!
compared! with! private! sequences! of! the! same! amino! acid! length.! Using! private! CDR3!




which! are! under! or! over! represented! compared! to! the! reference! set! in! each! sequence!
position!(Figure!42).!










































































The! incorporation! of! MID! labelling! within! these! experiments! allows! for! high;throughput!
sequencing!of!samples.!The!effect!of!a!multiplex!label!on!primer!efficiency!was!assessed!in!a!
number! of!ways.! Although!NCBI! BLAST! interrogation! revealed! that! targeting! of! the! primer!
was!not! influenced,!further!validation!stages! incorporated! in&silico!and!RT;PCR!testing.!Both!
of!these!methods!showed!suboptimal!efficiencies,!which!may!be!due!to!a!number!of!factors.!
Amplicons! should! ideally! be!50;150bp! in! length! for!optimal!RT;PCR!efficiency,! although! for!
standard! PCR! this! can! be! up! to! 500bp.! At! approximately! 500bp,! the! TCR! amplicon! could!
reduce! amplification! efficiency! when! assessed! through! the! means! of! RT;PCR.! This! is!
supported!by!the!fact!that!the!unlabelled!TRBC;R!primer!also!showed!suboptimal!efficiencies.!
Primer! Tm! was! raised! above! optimal! levels! by! the! addition! of! the! MID! label,! which! can!
increase!secondary!annealing.!Primers!were!chosen!to!sequence!full;length!TCR!VDJ!regions!
that! could! not! be! achieved! with! shorter! amplicon! length! and! therefore! redesign! of! these!
primers!was!not!an!option.!The!choice!of!target!cDNA!would!also!have!an!influence!on!PCR!
efficiency.!As!volumes!of!cDNA!for!use!in!the!second!round!PCR!were!very!limited,!the!choice!
was! taken! to! use! an! E.coli! colony! transformed!with! a! TCR! containing! vector! for! direct! PCR!
use.!Inhibition!of!PCR!can!occur!through!bacterial!cell!debris!due!to!high!colony!concentration!
or! presence!of! LB! agar.! Such! inhibition!may! reduce! PCR! efficiency! but! this!would! not! be! a!
factor!in!the!final!experiments.!!!
The!evaluation!of!MID!efficiencies!allowed!the!allocation!of!MIDs!with!approximately!equal!
efficiency!to! longitudinal!samples.! In!addition!the!RT;PCR!experiments! identified!MID!8!as!a!
primer!to!exclude!from!our!high;throughput!sequencing,!this!was!not!anticipated!through!in&
silico!analysis.!Although!in&silico!analysis!can!be!a!useful!initial!screen!for!PCR!design!it!can!fail!
to!account! for!all! the!components!within!an! in&vitro!PCR!reaction.!The!high!number!of!self;
dimers! and! the! presence! of! a! potential! G/C! quadruplex! in! the!MID! 8! labelled! primer!may!
have!been!a!limiting!factor!and!reflects!the!high!GC!content!(66.7%,!ideal!range:!40;60%).!!
During!data!analysis!the!effects!of!varying!cell!numbers!on!the!final!sequencing!was!carefully!
considered.! The! samples!were! limited! by! differing! cell! number! collection! and! the! need! for!
repeated! amplification! steps! to! provide! adequate! DNA,! statistical! analysis! was! used! to!
undertand!any!bias!introduced!through!these!limitations!and!if!adjustments!were!necessary.!
When! encountering! unequal! sample! sizes! it! is! suggested! that! normalisation! to! smallest!
sample!size!can!overcome!some!introduced!bias252,!however!within!these!samples!there!was!




considered! appropriate.! There! was! also! a! large! variation! in! cell! number! and! as! such!
normalisation!to!smallest!cell!number!samples!would!further!substantially!limit!data.!Absence!
of!correlation!was!also!seen!in!other!work!using!the!same!stimulation!assay!and!sequencing!
methods178.! The! effect! of! larger! cell! numbers! would! nonetheless! risk! bias! towards!
identification!of!rare!clonotypes!therefore!exclusion!of!single!clonotypes!was!used!in!diversity!
analysis.!Diversity!measures!were!limited!by!small!numbers!and!missing!data.!There!were!no!
detectable! significant! differences!between!groups!or! over! time,! although! there!was! a!non;
significant!trend!for!a!rise!in!Gini!index!mirrored!by!a!fall!in!true!diversity!in!the!low!frequency!
treatment!group,!suggesting!the!emergence!of!more!dominant!clonotypes!over!time.!
Within! the! clonotype! data,! sharing! of! β;chain! clonotypes! between! samples!was! commonly!
seen.!To!ensure! that! this!was!not!due! to!contamination!between!samples,! strict! laboratory!





antigen! specific! response! in! CD4+! T;cells,! sharing! of! isolated! TCR! α;chains! in! subjects!with!
T1D!was! commonly! found! by! Eugster! et! al.179.! This! study! showed! one! individual! with! T1D!
shared!5%!of!their!GAD;65!specific!TCR!α;chain!clonotypes!with!all!four!other!patients!tested!
and! shared! 35%! of! GAD;65! α;chain! clonotypes! with! at! least! one! other! patient.! However!
pairing! analysis! revealed! sharing! of! GAD;65! α;chain! clonotypes! did! not! correspond! to! a!
shared!β;chain!and!all!samples!which!shared!either!an!α;chain!or!β;chain!were!found!to!have!
a! unique! TCR! identity179.! Identical! α! and! β;chain! pairings! were! found! when! testing! two!




not! share! the! accompanying! paired! α! or! β;chains180.! The! presence! of! identical! β;chains!
matched!with! varying! α;chains!within! samples! from! the! same! individual!may! be! predicted!
through!the!temporal!relationship!of!α!and!β;chain!recombination.!As!successful!β;chain!VDJ!
recombination! results! in! the! productively! rearranged! gene! being! expressed! and! β;chain!
! ! 149! !
!
!
protein! associated! with! pTα! (a! surrogate! 33kDa! α;chain),! this! complexes! with! CD3! and!
expression!of!this!pre;T;cell!receptor!triggers!a!proliferative!burst!of!division!cycles!before!α;
chain!recombination!occurs254.!This!suggests!that!cells!with! identical!β;chain!clonotypes!but!
differing! α;chain! may! have! a! common! precursor! but! differentiation! of! α;chain! identity!
occurred!following!this!proliferative!burst.!!!
Published!literature!was!reviewed!for!previous!identification!of!the!shared!β;chain!sequences!
found! within! these! experiments.! The! Network! of! Pancreatic! Organ! Donors! with! Diabetes!
(nPOD)! has! collated! TCR! sequencing! data! from!donor! tissue! from!people!with! T1D,! type! 2!
diabetes! (T2D)! and! healthy! controls! into! its! TCR/BCR! Clonesearch! database255,! which! was!
screened! for! the! presence! of! shared! sequences.! Of! the! shared! clonotypes,! 39! individual!
amino! acid! sequences! were! found! in! the! nPOD! database! in! 33! donors! of! which! 18! had! a!
history! of! T1D,! but! such! sequences! were! also! found! in! donors! classified! with! no! diabetes!
(n=8),!T2D!(n=3),!gastric!bypass!(n=1),!AAb!positive!(n=1)!and!“other”!(n=2).!Sequences!with!
the!database!have!been!isolated!from!intraislet,!pancreatic!(pLN)!lymph!node,!non;pancreatic!
(iLN)! lymph! node,! PBMC! and! spleen.! Shared! sequences! were! found! across! all! these!
compartments!with! the! following! total! sequence!numbers! intraislet! (n=2),!pLN! (n=667),! iLN!
(n=184),!PBMC!(n=26)!and!spleen! (n=286).!The! two! intraislet! sequences!were! from!a!single!
nPOD! donor! with! T1D! and! consisted! of! a! single! CD8+! amino! acid! sequence!
CASSLGQGNQPQHF! from! two! separate! nucleotide! sequences.! However! this! sequence! was!
found!in!a!total!of!30!donors!including!those!who!did!not!have!T1D.!This!sequence!was!also!
found! in! unpublished! deep! sequencing! of! data! (courtesy! of! Dr! Iria! Gomez;Tourino)! again!
identifying!the!sequence!in!T1D!donors!and!healthy!controls!and!was!present!through!various!
T;cells! subsets,!namely! true!naïve,!central!memory!and!stem!cell!memory!T;cells.!The! large!
number!of!non;shared! sequences! limited! individual!nPOD!database! searches,!however! in! a!
small! sample!there!was!a!high!degree!of!matches! (9!out!of!15!sequences)! to!both!T1D!and!
non;diabetic! donors.! The! presence! of! shared! clonotypes! across! treatment! groups! and! in!
healthy! controls! or! T2D! and! the! presence! of! a! normally! distributed! CDR3! length! would!
suggest!that!these!clonotypes!do!not!indicate!immunodominance!through!either!presence!of!
PIT!or!disease!state.!!
Amino! acid! sequences! logos! from! iceLogo! show! that! there! is! significant! preferential! amino!
acid!usage!in!the!shared!CDR3!clonotypes.!There!is!evidence!to!show!that!hydrophobic!amino!
acid!usage! in!positions!P6!and!P7!of!the!CDR3!region!are!associated!with!self!reactivity!and!
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analysis.! In! addition! analysis! was! also! limited! by! the! identification! of! solely! β;chain!
sequences.!Without! information! on! α! chain! usage! and! αβ! pairing! we! cannot! fully! identify!
whether!shared!clonotypes!are!truly!identical.!Also!the!functional!diversity!of!the!sequenced!
antigen;specific!CD4+!cells!is!unknown!and!therefore!expansion!of!specific!clonotypes!cannot!
be! assigned! to! specific! sub;populations,! nor! can! cytokine! and! chemokine! responses! be!
predicted.!With!sequencing!data!only!the!PI!C19;A3!specific!cells,!there!is!no!comparable!data!
available!on!control!CD69+/CD154+!cells!and! therefore!we!cannot! test! if! these! findings!are!






expression!phenotype!of!TT! specific! cells! expressing! identical! TCR! receptor! clonotypes,! and!
were!able!to!quantify!distinct!cytokine!profiles!with!differential!expression!of! IFNγ,! IL;4!and!
FOXP3! genes.!Newer! technologies! such! as! these,! are! now!expanding! on! the! capabilities! of!
HTS! with! techniques! such! as! Fluidigm! capable! of! elucidating! combined! structural! and!
functional! identities! of! T;cells! with! sequencing! of! paired! αβ! TCR! chains! linked! to!
transcriptional!profiles182.!!This!enables!very!detailed!evaluation!of!small!T;cell!subsets!but!as!
throughput! capabilities! improve! and! cost! fall,! such! powerful! tools! will! significantly! further!
knowledge! in! both! autoimmune! disease! and! response! to! therapies! such! as! peptide!
immunotherapy.!!
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A! total! of! 96! samples! were! analysed! including! from! healthy! controls! (Table! 31).! Healthy!
control! samples! were! additional! samples! to! the! samples! provided! by! the! MonoPepT1De!
patients.!Patient!samples!were!chosen!prior!to!unblinding!of!the!trial!and!visit!1!and!visit!11!
samples! were! chosen! to! look! at! longitudinal! changes.! The! healthy! controls! consisted! of! 4!






of! 6! of! these! samples! having! small! cell! number! (≤200! cells)! but! all! samples! proceeded! to!
hybridization.!Hybridisation!was!repeated!in!a!number!of!these!samples!to!rule!out!technical!
issues! but! signal! intensities! remained! low.! Bioinformatic! analysis! of! microarray! data! was!
performed!by!Dr!Anna!Lorenc!(King’s!College!London).!This!confirmed!this!low!signal!intensity!
in! these! samples! despite! background! correction.! These! samples! were! not! included! in! the!
main!analysis!to!avoid!skewing!of!normalisation.!This!omission!of!data!had!impact!on!the!data!
sat!as!a!whole!as!pairing!of!samples!between!visit!1!!and!11!was!not!possible!as!a!result.!!




Samples& are& labelled& according& to& patient& number& and& where& applicable& visit& number.&
Numbers&indicate&cell&number&collected.&*&indicates&samples&that&with&low&signal&intensity.&
!! 1025!V1! 1025!V11! 2010!V1! 2010!V11!
Treatment! Placebo! High!Freq!
C19;A3!(CD69+/CD154+)! 2824! *2723! 305! 743!
HA!(CD69+/CD154+)! 2840! 3481! 381! 857!
C19;A3!(CD69;/CD154;)! 1000! 1000! 1000! 1000!
SEB!(CD69+/CD154+)! 9372! 15207! 5116! 5221!
! ! ! ! !!! 2017!V1! 2017!V11! 2021!V1! 2021!V11!
Treatment! High!Freq! High!Freq!
C19;A3!(CD69+/CD154+)! 161! 2175! 658! 1397!
HA!(CD69+/CD154+)! *128! 2729! 777! 1122!
C19;A3!(CD69;/CD154;)! 1000! 1000! 1000! 1000!
SEB!(CD69+/CD154+)! 922! 10000! 10000! 10000!
! ! ! ! !!! 3012!V1! 3012!V11! 3015!V1! 3015!V11!
!! Placebo! High!Freq!
C19;A3!(CD69+/CD154+)! 422! 2734! 1696! 664!
HA!(CD69+/CD154+)! 704! 3047! 2380! *1024!
C19;A3!(CD69;/CD154;)! 1000! 1000! 1000! 1000!
SEB!(CD69+/CD154+)! 10000! 9682! 10000! 10000!
! ! ! ! !!! 4001!V1! 4001!V11! 4005!V1! 4005!V11!
Treatment! Placebo! High!Freq!
C19;A3!(CD69+/CD154+)! 522! 952! *89! 756!
HA!(CD69+/CD154+)! !! !! *124! 863!
C19;A3!(CD69;/CD154;)! 1000! 1000! 1000! 1000!
SEB!(CD69+/CD154+)! 10000! 10000! 10000! 10000!
! ! ! ! !!! 4012!V1! 4012!V11! 5001!V1! 5001!V11!
Treatment! Placebo! Low!Freq!
C19;A3!(CD69+/CD154+)! 803! 2849! 867! 1014!
HA!(CD69+/CD154+)! 980! 3188! 932! 968!
C19;A3!(CD69;/CD154;)! 1000! 1000! 1000! 1000!
SEB!(CD69+/CD154+)! 10000! 10000! 9872! 10000!




Treatment! Placebo! Control! !!
C19;A3!(CD69+/CD154+)! !! !! 1782! !!
HA!(CD69+/CD154+)! !! !! 1576! !!
C19;A3!(CD69;/CD154;)! !! !! 1000! !!
SEB!(CD69+/CD154+)! 10000! 10000! 10000! !!





& & & &!! MP031! MP033! MP104!
!Treatment! Control! Control! Control!
!SEB!P7!(CD69+/CD154+)! 200! 200! *200!
!SEB!P7!(CD69+/CD154+)! 400! 400! 400!
!SEB!P7!(CD69+/CD154+)! 800! 800! 800!
!SEB!P7!(CD69+/CD154+)! 10000! 10000! 10000!
!!
7.3.1 Comparing&the&effect&of&cell&number&on&DGE.&&
Table! 31! illustrates! the! variability! in! cell! numbers! collected! in! samples.! The! control! SEB!
samples,!which!were!collected!in!samples!consisting!of!200,!400,!800!and!10,000!cells,!were!
incorporated!into!the!microarray!to!identify!the!influence!of!cell!number!on!gene!expression.!
To! interpret! the!effect!samples!were!split! into!4!bins! labelled!as,!extremely! low!(200!cells),!
low!(400!cells),!medium!(800!cells)!and!high!(10,000!cells).!Figure!43!shows!the!comparison!of!
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Figure& 43:& Volcano& plots& representing& gene& expression& between& CD69+/CD154+& SEB&
stimulated&control&samples&of&varying&sizes.&&
A3C&represent&genes&differentially&expressed&between&the&extremely&low&cell&number&samples&



















B. Modelling! the! effect! of! cell! number.! Using! the! control! SEB! stimulated! cell!
populations,!a!model!was!fitted!where!gene!expression!was!dependent!on!individual!
and!cell!number.! It!was!noted! that! splitting!samples! into!3! levels!of! cell!number!or!
bins! (very! low! (200! cells),! low! (400! cells)! high! (800! or! 10,000! cells)! in! the! analyses!








Method! A! resulted! in! no! significant! adjusted! p;values.! Method! B! showed! significant!
differences!only!in!C19;A3!stimulated!populations!(Table!32).!Comparable!data!using!model!C!
are!shown!in!Table!33.!Changes!in!gene!expression!were!also!seen!in!the!placebo!group,!so!to!
identify! whether! the! DGE! described! above! is! limited! to! the! treatment! group! only! gene!
expression!was!modelled!dependent!on!patients!before!treatment!(peptide!or!placebo)!and!
after!peptide!in!C19;A3!stimulated!cells.!This!results!in!non;significant!adjusted!p;values!in!all!
genes,! with! or! without! correction! for! cell! number.! The! 6! genes! found! have! DGE! in! both!
methods! B! and! C! and! were! submitted! to! KEGG257! Pathway!Mapper! and! the! Database! for!
Annotation,! Visualization! and! Integrated! Discovery! (DAVID)258! for! annotation! of! biological!
pathways!and!processes!which! these!genes!are! linked! to! (Table!34).!DGE! in!SEB!stimulated!
cells! pre! and! post! treatment! versus! placebo! showed! significant! adjusted! p;values! in! two!
genes! (Table! 35).! DGE! in! C19;A3! CD69;/CD154;! resting! cells! before! and! after! peptide!
treatment! versus! placebo! showed!only! one! gene!with! a! significant! adjusted! p;value! (Table!
36).!
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Of! the!peptide! treated!patients!we! compared! the! gene! expression! changes! seen! in! clinical!
responders!versus!non8responders.!Within!the!microarray!data!there!were!3!patients!in!each!
of!these!groups!all!of!which!had!a!high!cell!number.!Figure!44!summarises!the!presence!and!
relationship!of!DGE! in! the!subsets!of!cell!populations!between!clinical! responders!and!non8
responders!who!received!peptide!across!all!visits.! In! the!C198A3!resting!cells! there!were!11!
genes! with! greater! expression! in! non8responders! and! 5! with! greater! expression! in! the!
responders! (Table! 37),! and! in! the! HA! stimulated! cells! there! were! 4! genes! with! greater!
expression!in!the!responders!(Table!38).!
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Figure& 44:& Diagram& summarising& differentially& expressed& genes& found& in& metabolic&
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Gene! of! interest! identified! within! these! experiments! were! compared! to! those! genes!
identified!in!Burton!et!al.203!as!genes!linked!to!peptide!immunotherapy!in!a!mouse!model!of!
EAE.! Comparisons! of! 81! genes! identified! by! these! authors! were! examined! within! this!
microarray,!however!no!significant!DGE!was!present!when!examining!C198A3,!HA!stimulated!
cells!or!C198A3!resting!cells.!!
ImmuNet! (www.immunet.princeton.edu)! is! a! public! resource! providing! an! immunological8
pathway! focused! Bayesian! integration! of! over! 35,000! genome8scale! experiments! to! help!






smallest! adjusted!p8value!were! chosen! to! fit!with! ImmuNet! analysis.!A!number!of! immune!
specific! functional! networks! can! be! analysed! within! ImmuNet! and! 3! such! networks! were!
chosen!for!analysis:!immune!global,!antigen!processing!and!presentation!and!T8cell!receptor!
signalling.!!
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Figure& 47:& Functional& relationships& of& genes& found& to& have& DGE& post& peptide& treatment,&
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Figure& 50:& Functional& relationships& of& genes& upregulated& in& responders,& CYSLTR1,& NEK11,&
CHMP2A,& GCC2& and& SLC25A37& within& ImmuNet& antigen& presentation& and& processing&
network&
!
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Figure&51:& Functional& relationships&of&genes&upregulated& in&nonHresponders,&COX7B,& ITPA,&
ZFYVE21,&DYNLL1&and&FANCA&within&ImmuNet&global&immune&network&
!
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Figure&53:& Functional& relationships&of&genes&upregulated& in&nonHresponders,&COX7B,& ITPA,&






antigen! specific! CD69+/CD154+! cells,! which! not! only! lead! to! low! signal! intensity! on! the!






DGE! in! C198A3! stimulated! cells! pre! and! post! treatment! did! not! differ! significantly! from!
placebo!treated!individuals.!Whilst!this!suggests!that!gene!expression!changes!are!not!linked!
to!peptide!treatment!it!may!identify!changes!occurring!through!the!early!period!after!clinical!
diagnosis.! Six! genes! were! found! to! have! DGE! in! both! methods! B! and! C! to! adjust! for! cell!
number,! ATP6V1B1,! IL20,! ATP5G2,! JPH2,! LOC100130856! and! FAM221A.! Of! these! genes,!
LOC100130856!and!FAM221A!have!unknown!functions.!!





with! the! resolution! of! hyperglycaemia.! IL20! is! expressed! on! keratinocytes,! monocytes,!
granulocytes,! dendritic! cells! and! fibroblasts,! and! is! linked! to! psoriasis! and! rheumatoid!
arthritis.260!It!has!previously!been!identified!in!GWAS!studies!as!one!of!40!loci!associated!with!
risk! of! T1D15.! It! has! also! been! found! to! be! elevated! in! plasma! of! autoantibody! positive!
children261.! Junctophilins! are! junctional! membrane! complex! proteins! known! to! regulate!
calcium!signalling.!Whilst!the!junctophilin!4!has!been!recently!discovered!to!be!expressed!in!
T8cells262,! junctophilin!2! is!felt!to!be! largely!expressed!in!cardiac!and!skeletal!muscle263.! !For!
the!resting!C198A3!CD698/CD1548!cells!there!was!only!DGE!of!the!interferon!produced!protein!





admissions! for! diabetic! ketoacidosis.! Such! variation! will! have! impact! on! gene! expression!
levels!presumably!through!effects!of!hyperglycaemia!and!potentially!through!differing!levels!
of!immune!activation.!Between!visit!1!and!visit!11!there!was!a!significant!rise!in!cell!numbers!




Responder! gene!expression!analysis! showed!no!DGE! in!C198A3!CD69+/C154+! cells!but!DGE!
was!found!in!resting!C198A3!CD698/CD1548!cells!and!HA!CD69+/CD154+!cells,!indicating!that!
peptide!treatment!specific!changes!could!not!be! identified!within!these! limited!samples.!Of!




ImmuNet! was! chosen! to! analyse! the! gene! expression! data! as! it! offers! a! validated,! simple!
open8access! web! interface! to! explore! immune8related! functional! relationship! networks,!
which!offers!advantages!over!non8immune!focused!networks259.!Other!similar!options!such!as!
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the! Immunological! Genome! Project! (ImmGen)265! and! Immuno8Navigator266,! but! these! are!
established!using!mouse!data,!whereas!ImmuNet!has!the!advantage!of!using!human!datasets.!
The!ImmuNet!analysis!revealed!no!direct!functional!relationships!between!genes!identified!as!
having! differential! gene! expression! except! in! between! DYNLL1! and! COX7B,! which! were!
upregulated! in! non8responders! within! the! antigen! presentation! and! processing! pathways.!
When! looking! at! networks! identified! in! pre! and! post! treatment! DGE! there! appears! to! be!
greater! relationship! confidence! within! the! antigen! processing! and! presentation! network!
linked!to!the!ATP5G2!gene.!
!





This! thesis! reports! the! results! of! a!multicentre! placebo8controlled! peptide! immunotherapy!
trial!examining!the!use!of!proinsulin!C198A3!in!adults!newly!diagnosed!with!type!1!diabetes.!
In! addition,! the! validation! and! optimisation! of! immunological! assays! for! the! isolation! of!
antigen! specific! CD4! T8cells! and! subsequent! TCR! clonotyping! and! gene! microarray! are!
described.!!!!
Modern! treatments! for! T1D! are! still! sub8optimal! and! there! is! a! clear! rationale! for! peptide!
immunotherapy! as! an! intervention! in! this! autoimmune! disease.! With! rising! numbers! of!
mainly! paediatric! cases! being! diagnosed,! there! is! an! unmet! need! for! safe,! targeted!
treatments!aimed!at!amelioration!of!disease!over!the!current!focus!of!management,!which!is!
optimisation! of! insulin! replacement.! The! success! of! antigen8specific! immunotherapy! in! the!
field!of!allergy!has! led!to!translation! into!clinical!therapies;!and!prevention!trials! in!children!







and!stable!on! insulin,!unique!recruitment! issues!have!been!highlighted,!particularly!early! in!
the!course!of!T1D.!Importantly,!patient!perspectives!on!the!study!design!were!sought!which!
have! proved! helpful! for! design! of! further! trials.! A! number! of! methods! to! enhance!
engagement! and! drive! screening! have! been! described,! notably! the! using! established!




of! this! study,! the!establishment!of! the!T1DUK!Consortium!has!promoted!and! strengthened!
the!presence!of!T1D!immunotherapy!in!the!UK!and!there!has!been!a!wide!expansion!of!T1D!
social! media! communities.! One! of! the! aims! of! this! is! to! aid! self8referral! and! clinical! team!
identification!for!immunotherapy!studies.!To!further!streamline!recruitment,!protocol!design!
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matched!with!our! inclusion!criteria.!Our!data! showed!a!higher!percentage!of!GAD,! IA2!and!
ZnT8! antibody! negative! subjects! with! more! frequent! GAD! responses,! which! could! be!
explained! by! differences! in! cohort! age,! assay!methods! and! possibly! geographical! genotype!
distribution.!In!the!screening!population,!ZnT8!assays!were!able!to!distinguish!an!extra!7%!of!
antibody! positive! individuals! over! GAD! alone! but! IA2! did! not! confer! any! additional!





positive!HLA5DRB1*0401( individuals! exceeded! this! threshold.! This! suggests! that!within! our!
inclusion! criteria,! 3.6%! are! rapid! progressors! in! which! C8peptide! reserve! declines!
precipitously! within! this! narrow! window.! Evidence! suggests! children! progress! even! more!
rapidly! in! terms! of! C8peptide! loss! than! this! adult! cohort! with! 9%! of! those! under! 8! falling!
below!the!peak!stimulated!C8peptide!of!>0.2pmol/mL!at!diagnosis230.!This!should!strengthen!
the! argument! for! early! identification! and! prevention! strategies,! as! there! is! a! significant!
proportion! of! rapid! progressors! who!may! be! at! greater! risk! of! complications! due! to! early!
decline58.!!!!((
Whilst! stimulated! C8peptide! AUC! is! the! most! commonly! used! parameter! to! assess! β8cell!
function,!other!simpler,!less!invasive!biomarkers!are!being!sought.!In!our!data!we!saw!fasting!
C8peptide!correlating!well!with!C8peptide!AUC! figures!but! further!validation! is!necessary!as!
fasting! C8peptide! levels! may! not! fully! reflect! dynamic! changes! in! C8peptide! response.! C8
peptide!AUC!was!not!normally!distributed!and!was!positively!skewed!possibly!due!to!the!BMI!
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in!established!T1D!did!not!correlate!well!with!stimulated!C8peptide! levels! in! the!early!post8
diagnosis!period!due!to!high!variabiity229.!!
The! peptide! proinsulin! C198A3!was! chosen! due! to! its! immunological! relevance! to! T1D! and!
previous!data! in!established!T1D!subjects.!Being!part!of!a!panel!of!peptides!from!proinsulin!
naturally! processed! and! presented! by! the! high! risk! HLA! DR4! molecule,! proinsulin! C198A3!
elicited!a!strong!polarisation!of!ELISPOT!responses!for!inflammatory!IFNγ!in!T1D!subjects!and!
IL810!in!healthy!controls75.!!A!subsequent!clinical!trial!established!safety!in!people!with!long8
standing! T1D! with! the! suggestion! of! favourable! immunological! responses! in! certain!
individuals!who!showed! increased! in! IL810!or!decreases! in! IFNγ!stimulation! indexes117.! !The!
MonoPepT1De!trial!strengthens!the!safety!profile!of!this!approach,!as!it!has!established!that!
there! were! no! significant! risks! from! high! or! low! frequency! treatment! in! terms! of!
hypersensitivity!or!acceleration!of!disease.!This!is!in!keeping!with!the!safety!profile!of!PIT!in!
allergy.! Decline! in! C8peptide! was! significantly! lower! in! the! high! frequency! PIT! group! at! 3!
months!than!placebo!and!other!metabolic!measures!were!reflective!of!this!difference.!These!
suggested!that!those!receiving!peptide!treatment!showed!no!differences!in!HbA1c!over!time!
or! compared! to! baseline,! but! increases! in! insulin! doses! from! baseline! were! significantly!
higher! in! the! placebo! group! at! 6,! 9! and! 12! months! despite! a! non8significant! trend! for!
increasing! HbA1c.! IDAA1c,! a! composite! measure! of! residual! β8cell! function! was! higher! at!
baseline! in! the! placebo! and! continued! to! be! significantly! higher! throughout! the! trial.!
Immunological!assays!were!able!to!identify!higher!IL810!levels!in!peptide8treated!responders!
across! the! treatment! period,! with! a! greater! increase! in! Treg! expression! of! FoxP3! from!
baseline! to! 6!months! in! peptide! treated8responders! than! non8responders.! There!were! also!
higher!cumulative!CD4!T8cell! IL810!responses! in!the!high!frequency!group!over!the!6!month!
treatment! period.! These! changes! are! in! keeping! with! postulated! mechanisms! of! immune!
regulation! through! peptide! immunotherapy,! however! as! with! metabolic! data,! baseline!
immune!differences!in!response!may!be!present!and!we!were!unable!to!show!clear!changes!
in! IL810! or! IFNγ! from!baseline! in! treatment! groups.!Our! experiments!were! able! to! identify!
changes! in! Treg! subsets! with! significant! changes! in! memory! Tregs! expressing! CD39+! and!





! ! 174! !
!
!




differences! in! baseline! data! limit! interpretation! of! secondary! outcomes! data! and! further!








immunotherapy! may! offer! advantages! over! single! peptide239.! Using! a! transgenic! mouse!
expressing!human!DR4!as!a! translational!model!of!T1D,!Gibson!et!al.239!were!able! to!break!
tolerance! to! proinsulin! by! sensitising! with! complete! Freund’s! adjuvant,! in! addition! to! two!
doses! of! pertussis! toxin! at! day! 0! and! 1.! Subsequently! the! HLA8DR4! transgenic! mice! show!
autoinflammatory! responses,! including! proinsulin8specific! T8cell! proliferation,! IFNγ! and!
autoantibody! production.! This! model! could! then! be! used! to! explore! PIT! regimens! with!
treatment! pre8! and! post8induction! reducing! autoinflammatory! responses.! Levels! of!
proliferating! FoxP3! Tregs! isolated! from! lymph! nodes! were! significantly! higher! following!
multiple!peptide!imunotherapy!than!control!peptide!which!was!not!seen!with!single!peptide!
PIT.! Similarly! multiple! peptide! immunotherapy! was! effective! at! down! modulating! the!
response!to!proinsulin!protein!in(vivo,!by!reducing!serum!levels!of!proinsulin8specific!IgG!to!a!
greater! degree! than! single! peptides.! Whilst! preclinical! animal! studies! can! be! helpful,!
experience!in!immunotherapy!in!T1D!shows!us!that!translating!results!to!human!studies!can!
often! yield! differing! outcomes,! suggesting! fundamental! differences! between! these!models!
and!human!pathophysiology.!A!phase! I! clinical! trial!of!PIT!using!multiple! islet!autoantigens,!
the!MultiPepT1De!trial!(ClinicalTrials.gov!identifier:!NCT02620332)!is!currently!in!progress!in!
people!who!have!a!duration!of!T1D!of!up!to!4!years.!!
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Within! the! study,! steps!were! taken! to!optimise! assays,!which! for! TCR! clonotyping! involved!
validation!of!multiplexing!techniques!for!high8throughput!sequencing.!Whilst!TCR!clonotyping!
was!limited!to!solely!β8chain!sequencing!the!findings!support!other!literature!where!there!is!
common! sharing! of! β8chain! clonotypes! but! this! is! not! limited! to! T1D! or! autoimmunity.!
Evidence!suggests!that!sharing!of!β8chain!clonotypes!does!not!reflect!identical!αβ!pairing179;!
therefore! disease! or! treatment8specific! interpretation! of! the! significance! of! such! public! β8
chain! clonotypes! is! limited!without!wider! data.! Improving! technologies! have! expanded! the!
capabilities!of! TCR! sequencing!with! subsequent! recent! studies! in!our! laboratory!having! the!
capacity! for! single8cell! paired! αβ! chain! sequencing! incorporating! cell! phenotyping! through!
flow! cytometry! and! transcriptional! analysis.! The! microarray! data! generated! in! this! thesis!
showed!no!difference! in!gene!expression! in!C198A3!stimulated!cells!post!PIT!within! treated!
patients! as! a! whole! or! in! responders.! Whilst! peptide! specific! changes! were! not! present,!
changes! in! gene! expression!were! present! in! peptide! and! placebo! treated! groups! and!may!
indicate!changes!present!early!after!clinical!diagnosis.!Also!within!responders!there!was!DGE!




and! established! the! safety! of! this! approach! at! clinical! diagnosis! over! a! 6!month! treatment!
period,! with! very! favourable! safety! outcomes! in! both! hypersensitivity! and! importantly!
absence! of! disease! exacerbation.! The! approach! offers! clear! advantages! to! other! therapies!
and! its! safety! indicates! it! is! a! valid! option! for! children,! as! an! intervention! at! diagnosis! or!
potentially! in! disease! prevention.!With! autoreactive! CD8! T8cell! CD57! expression! present! at!
lower!levels!in!responders,!this!would!suggest!that!PIT!would!be!ideally!suited!as!an!agent!in!
primary! prevention.! Optimisation! of! PIT! may! require! multiple! peptides! as! supported! by! a!
preclinical!T1D!model239!and!a!further!clinical!study!incorporating!use!of!C198A3!peptide!into!
a! multiple! PIT! is! currently! ongoing.! Combination! treatments! with! non8antigen! specific!
treatments!may!offer!synergistic!effects!with!ASI.!The!HLA!restriction!of!C198A3!PIT!currently!




individuals,! and! this! has! hindered! biomarker! discovery.! ! In! view! of! this! heterogeneity,! the!
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